<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T20:07:55Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:6003972" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:6003972</identifier><datestamp>2018-06-29</datestamp><setSpec>springeropen</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Cell Mol Life Sci</journal-id>
      <journal-id journal-id-type="iso-abbrev">Cell. Mol. Life Sci</journal-id>
      <journal-title-group>
        <journal-title>Cellular and Molecular Life Sciences</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1420-682X</issn>
      <issn pub-type="epub">1420-9071</issn>
      <publisher>
        <publisher-name>Springer International Publishing</publisher-name>
        <publisher-loc>Cham</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC6003972</article-id>
      <article-id pub-id-type="pmcid">PMC6003972</article-id>
      <article-id pub-id-type="pmc-uid">6003972</article-id>
      <article-id pub-id-type="pmid">29428966</article-id>
      <article-id pub-id-type="publisher-id">2757</article-id>
      <article-id pub-id-type="doi">10.1007/s00018-018-2757-4</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>SLC52A3 expression is activated by NF-ÎºB p65/Rel-B and serves as a prognostic biomarker in esophageal cancer</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Long</surname>
            <given-names>Lin</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pang</surname>
            <given-names>Xiao-Xiao</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lei</surname>
            <given-names>Fei</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>Jia-Sheng</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>Wei</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Liao</surname>
            <given-names>Lian-Di</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Xu</surname>
            <given-names>Xiu-E</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>He</surname>
            <given-names>Jian-Zhong</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wu</surname>
            <given-names>Jian-Yi</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wu</surname>
            <given-names>Zhi-Yong</given-names>
          </name>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>Li-Dong</given-names>
          </name>
          <xref ref-type="aff" rid="Aff5">5</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Lin</surname>
            <given-names>De-Chen</given-names>
          </name>
          <address>
            <email>lindch5@mail.sysu.edu.cn</email>
          </address>
          <xref ref-type="aff" rid="Aff6">6</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Li</surname>
            <given-names>En-Min</given-names>
          </name>
          <address>
            <email>nmli@stu.edu.cn</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1618-4292</contrib-id>
          <name>
            <surname>Xu</surname>
            <given-names>Li-Yan</given-names>
          </name>
          <address>
            <phone>+86-754-88900460</phone>
            <email>lyxu@stu.edu.cn</email>
          </address>
          <xref ref-type="aff" rid="Aff2">2</xref>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0605 3373</institution-id><institution-id institution-id-type="GRID">grid.411679.c</institution-id><institution>Department of Biochemistry and Molecular Biology, </institution><institution>Shantou University Medical College, </institution></institution-wrap>Shantou, China </aff>
        <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0605 3373</institution-id><institution-id institution-id-type="GRID">grid.411679.c</institution-id><institution>The Key Laboratory of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area, </institution><institution>Shantou University Medical College, </institution></institution-wrap>Shantou, China </aff>
        <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0605 3373</institution-id><institution-id institution-id-type="GRID">grid.411679.c</institution-id><institution>Institute of Oncologic Pathology, </institution><institution>Shantou University Medical College, </institution></institution-wrap>Shantou, 515041 Guangdong China </aff>
        <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.452734.3</institution-id><institution>Department of Oncology Surgery, </institution><institution>Shantou Central Hospital, Affiliated Shantou Hospital of Sun Yat-Sen University, </institution></institution-wrap>Shantou, China </aff>
        <aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2189 3846</institution-id><institution-id institution-id-type="GRID">grid.207374.5</institution-id><institution>Henan Key Laboratory for Esophageal Cancer Research, Department of Basic Oncology and Pathology at College of Medicine, The First and The Second Affiliated Hospital, </institution><institution>Zhengzhou University, </institution></institution-wrap>Zhengzhou, Henan China </aff>
        <aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2360 039X</institution-id><institution-id institution-id-type="GRID">grid.12981.33</institution-id><institution>Guangdong Province Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Research Center of Medicine, Sun Yat-Sen Memorial Hospital, </institution><institution>Sun Yat-Sen University, </institution></institution-wrap>Guangzhou, China </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>10</day>
        <month>2</month>
        <year>2018</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>10</day>
        <month>2</month>
        <year>2018</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <year>2018</year>
      </pub-date>
      <volume>75</volume>
      <issue>14</issue>
      <fpage>2643</fpage>
      <lpage>2661</lpage>
      <history>
        <date date-type="received">
          <day>15</day>
          <month>10</month>
          <year>2017</year>
        </date>
        <date date-type="rev-recd">
          <day>16</day>
          <month>1</month>
          <year>2018</year>
        </date>
        <date date-type="accepted">
          <day>18</day>
          <month>1</month>
          <year>2018</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Â© The Author(s) 2018</copyright-statement>
        <license license-type="OpenAccess">
          <license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <p id="Par1">The human riboflavin transporter-3 (encoded by <italic>SLC52A3</italic>) plays a prominent role in riboflavin absorption. Interestingly, abnormal expression patterns of SLC52A3 in multiple types of human cancers have been recently noted. However, the molecular mechanisms underlying its dysregulation remain unclear. In this study, we find that SLC52A3 has two transcript variants that differ in the transcriptional start site, and encode different proteins: SLC52A3a and SLC52A3b. Importantly, aberrant expressions of SLC52A3 are associated with stepwise development of esophageal squamous cell carcinoma (ESCC) as well as the survival rates of ESCC patients. Functionally, SLC52A3a, but not SLC52A3b, strongly promotes the proliferation and colony formation of ESCC cells. Furthermore, <italic>SLC52A3</italic> 5â²-flanking regions contain NF-ÎºB p65/Rel-B-binding sites, which are crucial for mediating <italic>SLC52A3</italic> transcriptional activity in ESCC cells. Chromatin immunoprecipitation and electrophoretic mobility shift assay reveal that p65/Rel-B bind to 5â²-flanking regions of <italic>SLC52A3</italic>. Accordingly, NF-ÎºB signaling upregulates SLC52A3 transcription upon TNFÎ± stimulation. Taken together, these results elucidate the mechanisms underlying SLC52A3 overexpression in ESCC. More importantly, our findings identify SLC52A3 as both a predictive and prognostic biomarker for this deadly cancer.</p>
        <sec>
          <title>Electronic supplementary material</title>
          <p>The online version of this article (10.1007/s00018-018-2757-4) contains supplementary material, which is available to authorized users.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>SLC52A3</kwd>
        <kwd>Riboflavin</kwd>
        <kwd>TNFÎ±</kwd>
        <kwd>NF-ÎºB</kwd>
        <kwd>Rel-B</kwd>
        <kwd>Esophageal cancer</kwd>
      </kwd-group>
      <funding-group>
        <award-group>
          <funding-source>
            <institution>Natural Science Foundation of China-Guangdong Joint Fund</institution>
          </funding-source>
          <award-id>No. U1301227</award-id>
          <award-id>U1601229</award-id>
          <principal-award-recipient>
            <name>
              <surname>Li</surname>
              <given-names>En-Min</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>Li-Yan</given-names>
            </name>
          </principal-award-recipient>
        </award-group>
      </funding-group>
      <funding-group>
        <award-group>
          <funding-source>
            <institution>National Cohort of Esophageal Cancer of China</institution>
          </funding-source>
          <award-id>No. 2016YFC0901400</award-id>
          <principal-award-recipient>
            <name>
              <surname>Xu</surname>
              <given-names>Li-Yan</given-names>
            </name>
          </principal-award-recipient>
        </award-group>
      </funding-group>
      <funding-group>
        <award-group>
          <funding-source>
            <institution-wrap>
              <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id>
              <institution>National Natural Science Foundation of China</institution>
            </institution-wrap>
          </funding-source>
          <award-id>81772532</award-id>
          <award-id>81472613</award-id>
          <award-id>81672786</award-id>
          <principal-award-recipient>
            <name>
              <surname>Lin</surname>
              <given-names>De-Chen</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>En-Min</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>Li-Yan</given-names>
            </name>
          </principal-award-recipient>
        </award-group>
      </funding-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>Â© Springer International Publishing AG, part of Springer Nature 2018</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Introduction</title>
      <p id="Par11">Esophageal squamous cell carcinoma (ESCC) is the sixth most lethal malignancy in China, with an incidence of 21.62/10<sup>5</sup> [<xref ref-type="bibr" rid="CR1">1</xref>]. Nutritional imbalance has been suggested as one of the risk factors for ESCC [<xref ref-type="bibr" rid="CR2">2</xref>â<xref ref-type="bibr" rid="CR5">5</xref>]. Notably, a few reports indicated that lack of dietary riboflavin was associated with high risk for ESCC [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. However, the biological significance of riboflavin in the context of ESCC remains unknown. Many studies suggested that riboflavin played a role in immune system. Particularly, riboflavin deficiency affects cytokine production, and riboflavin-deprived cells released less IL-10 (anti-inflammatory) and more TNFÎ± (pro-inflammatory) [<xref ref-type="bibr" rid="CR8">8</xref>â<xref ref-type="bibr" rid="CR11">11</xref>].</p>
      <p id="Par12">Human riboflavin transporter-3 (encoded by <italic>SLC52A3</italic>) is a trans-membrane protein that has been shown to play an important role in the absorption of riboflavin and regulation of riboflavin tissue distribution [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. Humans and other mammals (which lack the ability to synthesize riboflavin endogenously) obtain riboflavin from exogenous sources including dietary and normal microflora of large intestine [<xref ref-type="bibr" rid="CR14">14</xref>]. SLC52A3 was reported as the most efficient transporter of riboflavin [<xref ref-type="bibr" rid="CR15">15</xref>]. Notably, different groups found that riboflavin deficiency increased the expression of SLC52A3 [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>], implying a negative feedback regulatory mechanism maintaining riboflavin homeostasis.</p>
      <p id="Par13">SLC52A3 has been implicated in the biology of several tumor types, including those from stomach and cervix [<xref ref-type="bibr" rid="CR17">17</xref>â<xref ref-type="bibr" rid="CR19">19</xref>]. It was also reported that SLC52A3 is upregulated in ESCC and glioma, compared with nonmalignant adjacent tissue. Moreover, SLC52A3 enhanced the proliferation of ESCC and glioma cells [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. However, little is known concerning how the expression of SLC52A3 is regulated at the transcriptional level in ESCC cells. More importantly, the clinical significance and biological relevance of SLC52A3 expression remain to be elucidated.</p>
    </sec>
    <sec id="Sec2">
      <title>Materials and methods</title>
      <sec id="Sec3">
        <title>Cell cultures and treatment</title>
        <p id="Par14">Cell lines used in this study were previously described [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. ESCC cell lines (KYSE150, KYSE180, KYSE510, and TE3) were maintained in 1640 medium (Thermo Fisher Scientific) containing 10% fetal bovine serum (GIBCO). SHEEC and SHEE cells were cultured in Dulbeccoâs modification of Eagleâs medium Dulbecco (DMEM)/F12 medium (Thermo Fisher Scientific) with 10% newborn bovine serum (ExcellBiology). Immortalized esophageal epithelial cell lines (NE2 and NE3) were cultured in a 1:1 mixture of defined keratinocyte serum-free medium (Thermo Fisher Scientific) and EpiLife (Thermo Fisher Scientific). HEK293T cells were cultured in Dulbeccoâs modified Eagleâs medium (Thermo Fisher Scientific) supplemented with 10% fetal bovine serum. All cells were incubated at 37Â Â°C in a humidified atmosphere of 5% CO<sub>2</sub> in air and maintained in media supplemented with penicillin-G (100Â units/mL) and streptomycin (100Â Î¼g/mL).</p>
        <p id="Par15">In functional assays, KYSE150 and KYSE510 cells were seeded into 60Â mm cell culture dishes at the density of 5Â ÃÂ 10<sup>5</sup> cells per dish and treated with various concentrations TNFÎ± (0, 20, 100 or 200Â ng/mL, an NF-ÎºB inducer, Promega) for 0, 3, or 6Â h, respectively. In drug treatment experiments, cells were pretreated with QNZ (500Â nM, a NF-ÎºB inhibitor, Selleck) or JSH-23 (300Â nM, an NF-ÎºB inhibitor, Selleck) for 24Â h, followed by TNFÎ± (20Â ng/mL, ab NF-ÎºB inhibitor, Promega) treatment for 6Â h.</p>
      </sec>
      <sec id="Sec4">
        <title>Sample collection and tissue microarray construction</title>
        <p id="Par16">For the retrospective survival analysis study, immunohistochemical staining was performed on ESCC tissue microarrays (TMA) constructed from paraffin-embedded specimens surgically resected at Shantou Central Hospital from 1987 to 1997 (246 cases) and 2007 to 2014 (290 cases). Tissue microarrays were constructed based on standard techniques as previously described [<xref ref-type="bibr" rid="CR24">24</xref>]. Information on gender, age, stage of disease, and histopathologic characteristics was obtained from the medical records. Patientsâ data were summarized in Supplementary Table S1 and Table S2. Data analysis indicated that there were no survival advantages associated with the use of radiotherapy or chemotherapy compared with the surgery-alone group, so we assessed the patientsâ survival together. KaplanâMeier survival evaluation revealed that the prognosis of patients was significantly associated with the histological grade, regional lymph node metastasis, and pTNM stage (<italic>P</italic>Â &lt;Â 0.05). The patients who suffered from severe post-operative complications and those who died of other tumors or other causes were excluded. The study was approved by the governmental ethics committee.</p>
        <p id="Par17">To find out the expression pattern of SLC52A3 during the progression from normal esophagus to ESCC, 39 paraffin-embedded specimens resected at Shantou Central Hospital were selected for immunohistochemical analysis in the study. The normal esophagus and some lesions of hyperplasia, high-grade dysplasia, including all noninvasive neoplastic epithelia, previously called carcinoma in situ, and ESCC were evaluated in each sample. The normal epithelia were seen in 20 samples, while hyperplasia was present in 13 cases, lesions of high-grade dysplasia in 21 sections, and ESCC tissues in 37 of the 39 samples.</p>
      </sec>
      <sec id="Sec5">
        <title>SLC52A3a and SLC52A3b polyclonal antibody production</title>
        <p id="Par18">Rabbit anti-SLC52A3a and anti-SLC52A3b polyclonal antibody were produced by Zhoushan Bio-Technique Co., Ltd., Shandong, China. They used human SLC52A3a-unique sequence LRLFSSADFCNLHCPA (16 C-terminal amino acids) and SLC52A3b-unique sequence SIRPVGLLPLRTPHP (15 C-terminal amino acids) designed immunizing peptide and confirmed their stringent specificity using recombinant human SLC52A3 polypeptide by western blot.</p>
      </sec>
      <sec id="Sec6">
        <title>Immunohistochemical staining</title>
        <p id="Par19">Immunohistochemistry (IHC) was performed as described in our previous studies [<xref ref-type="bibr" rid="CR25">25</xref>]. Briefly, sectionsÂ 4Â Î¼m thick were dewaxed in xylene, rehydrated in alcohol, and incubated in 3% hydrogen peroxide for 10Â min to block endogenous peroxidase activity. Sections were incubated with 10% normal goat serum in PBS for 15Â min at room temperature to block nonspecific binding. Then sections were incubated overnight at 4Â Â°C with primary antibodies for SLC52A3 antibody (1:50, Abgent), SLC52A3a antibody (1:50, Zhoushan Bio-Technique), or SLC52A3b antibody (1:50, Zhoushan Bio-Technique). After rinsing with PBS, slides were incubated for 10Â min at 37Â Â°C with HRP Polymer Conjugate (ZYMED, USA). Subsequently, slides were stained with 0.003% 3,3-diaminobenzide tetrahydrochloride and 0.005% hydrogen peroxide in 0.05Â M TrisâHCl (pH 7.2), and counterstained with hematoxylin, dehydrated, and mounted. Positive reactions were defined as those showing brown signals in the esophageal squamous cell cytoplasm, nucleus or membrane. Each separate tissue core was scored on the basis of the intensity and area of the positive staining. The intensity of positive staining was scored: 0, negative; 1, weak staining; 2, moderate staining; 3, strong staining. The percentage of positive cells was scored on a 0â4 scale: 0, 0â5%; 1, 6â25%; 2, 26â50%; 3, 51â75%; 4,Â &gt;Â 75%. The total score was obtained by multiplying the two scores above producing a total score range of 0â12. For statistical analysis, we treated all the samples with a total score of 0â4 as low (â) and of 5â12 as high (+).</p>
      </sec>
      <sec id="Sec7">
        <title>Mapping of the SLC52A3 gene transcriptional start sites (TSSs)</title>
        <p id="Par20">Total RNA from cell lines were extracted using TRIzol reagent (Invitrogen). Reverse transcription and rapid amplification of cDNA ends (RACE) was performed with the 5<bold>â²</bold>-Full RACE Kit (TaKaRa, Dalian, China) in accordance with the manufacturerâs instructions. The final PCR product was extracted and purified from 2% agarose gel, cloned into pGEM-T Vector (Promega). Plasmid DNA from four different colonies was sequenced. Gene-specific primers used for 5â²RACE experiments were listed in Supplementary Table S3.</p>
      </sec>
      <sec id="Sec8">
        <title>Cloning and sequence analysis of full-length SLC52A3 cDNA</title>
        <p id="Par21">SLC52A3 sequences were cloned by reverse transcriptase polymerase chain reaction (RT-PCR). Briefly, RNA was extracted from ESCC cell lines (EC8712) with TRIzol reagent (Invitrogen) and reverse transcribed using a reverse transcription system (TaKaRa). SLC52A3a and SLC52A3b coding sequences were amplified using the cloning primers listed in Supplementary Table S3, after which they were ligated into the pEASY-Blunt Simple Cloning Vector (TRANSGEN BIOTECH) and verified by complete sequencing.</p>
      </sec>
      <sec id="Sec9">
        <title>Construction of GFP-tagged SLC52A3a and SLC52A3b expression plasmids</title>
        <p id="Par22">The coding region of SLC52A3a and SLC52A3b was amplified and cloned into the <italic>Hin</italic>dIII and <italic>Bam</italic>HI sites of pEGFP-C1 vector (Clontech) to generate the GFP-SLC52A3a and GFP-SLC52A3b expression vector.</p>
      </sec>
      <sec id="Sec10">
        <title>Confocal immunofluorescence microscopy</title>
        <p id="Par23">The immunofluorescence staining was performed as described previously [<xref ref-type="bibr" rid="CR26">26</xref>]. In brief, GFP-tagged SLC52A3a and SLC52A3b constructs were transfected into KYSE150 cells. At 48Â h post-transfection, the cells were fixed in 4% paraformaldehyde for 10Â min, after which they were rinsed with PBS and permeabilized in 0.1% Triton X-100 for 10Â min. Nonspecific binding was blocked by incubating the cells with 5% normal donkey serum (Jackson ImmunoResearch) in PBS for 60Â min. Subsequently, cells were incubated with antibodies against GFP (Santa Cruz Biotechnology), and then, cells were probed with the Alexa Fluor 488-conjugated AffiniPure donkeyâanti-mouse secondary antibody (Jackson ImmunoResearch) and counterstained with DAPI (Sigma-Aldrich). Cells were analyzed using a Zeiss LSM880 confocal microscope (Zeiss). For common cell immunofluorescence, cells were seeded on a coverslip and incubated for 24Â h. Pass by fixation and blocking, cells were incubated with primary SLC52A3 polyclonal antibodies (Abgent) in PBS for 4Â h at room temperature and were probed with donkeyâanti-rabbit Dylight 594 secondary antibodies (Jackson ImmunoResearch) in PBS for 1Â h. To visualize the cell nucleus, cells were incubated with DAPI (Sigma-Aldrich) for 15Â min and were imaged using an FV-1000 confocal microscopy (Olympus).</p>
      </sec>
      <sec id="Sec11">
        <title>shRNA lentivirus-mediated knockdown of SLC52A3</title>
        <p id="Par24">Recombinant lentivirus vectors pHBLV-U6-Luc-T2A-Puro harboring a short-hairpin RNA sequence targeting SLC52A3 (shSLC52A3-4#, shSLC52A3-6#, and control-shRNA) were produced by Hanbio Co., Ltd (Shanghai, China). To generate cells stably expressing shSLC52A3-4#, 6#, or the control-shRNA, lentivirus were used to infect KYSE180 and SHEEC cells, following the manufacturerâs instructions, when cells reached 40â50% confluence. Twenty-four hours later, cells were selected in medium containing 0.5Â mg/mL puromycin (AMRESCO) for 20Â days. After 4â5 passages in the presence of puromycin, the cultured cells were used for experiments.</p>
      </sec>
      <sec id="Sec12">
        <title>Adenovirus-mediated overexpression of SLC52A3a and SLC52A3b</title>
        <p id="Par25">To generate cells overexpressing SLC52A3a and SLC52A3b, the SLC52A3a and SLC52A3b CDS sequences were ligated into the pHBAd-MCMV-Luc Vector (Hanbio Co., Ltd., Shanghai, China). Then, KYSE150 and KYSE180 cells were infected with adenoviral vectors overexpressing SLC52A3a (Ad-SLC52A3a), SLC52A3b (Ad-SLC52A3b), or control adenovirus (Ad-Luc), at the MOI (multiplicity of infection) of 100 after 24Â h of seeding. Thirty-six hours later, cells were passaged or harvested for further analysis.</p>
      </sec>
      <sec id="Sec13">
        <title>Cell proliferation assay</title>
        <p id="Par26">All cells were seeded in 96-well plates at 8000 cells per well. The CellTiter 96 aqueous nonradioactive cell proliferation assay was performed according to the manufacturerâs instructions (Promega) at 0, 24, 48, 72, and 96Â h, respectively. 20Â Î¼L MTS was added to each well, and the plates were incubated for 2Â h at 37Â Â°C in a humidified, 5% CO<sub>2</sub> atmosphere. MTS was bioreduced by the cells into a colored formazan product that displays absorbance at 490Â nm. The absorbance was detected using a plate microplate reader (Multiskan MK3, Thermo). Raw data were normalized against those of the medium blank control.</p>
      </sec>
      <sec id="Sec14">
        <title>Colony formation assay</title>
        <p id="Par27">Colony formation assay was performed as described previously [<xref ref-type="bibr" rid="CR27">27</xref>]. Briefly, transfected cells were plated at a density of 1000 cells per well in 6-well plates and incubated for 14Â days at 37Â Â°C with 5% CO<sub>2</sub>. After washing with 4Â Â°C pre-cooled PBS, cultures were fixed with ice-cold methanol for 20Â min and stained with hematoxylin for 15Â min. Colonies were photographed and calculated using a FluorChem 8900 image analysis system (Alpha Innotech, Miami, FL, USA). Each experiment was performed in triplicate.</p>
      </sec>
      <sec id="Sec15">
        <title>Measurement of riboflavin</title>
        <p id="Par28">Both intra- or extra-cellular concentrations of riboflavin were measured by high-performance liquid chromatography (HPLC) as described previously [<xref ref-type="bibr" rid="CR28">28</xref>]. Briefly, cells were plated at a density of 2Â ÃÂ 10<sup>5</sup> cells per well in 6-well plates, and culture medium was collected after 0, 24, 48, and 72Â h, respectively, while cells were collected after 72Â h. The concentrations of riboflavin in the collected culture medium were measured directly by HPLC. Cells were lysed byÂ ultrasonic wave and riboflavin concentrations were measured by HPLC.</p>
      </sec>
      <sec id="Sec16">
        <title>Reporter gene constructs</title>
        <p id="Par29">The human SLC52A3 5â²-flanking region âÂ 5076/âÂ 2403 (translation initiation site for the SLC52A3 protein occurs at +Â 1) was generated by PCR using primers SLC52A3-5â²FR-1F and SLC52A3-5â²FR-1R (Supplementary Table S3). The amplified fragment from the genomic DNA of KYSE180 cells was digested with <italic>Xho</italic>I/<italic>Bgl</italic>II and inserted into the <italic>Xho</italic>I/<italic>Bgl</italic>II sites of pGL4.15[luc2P/Hygro] Vector (Promega), and the resulting plasmid was named pGL4 (âÂ 5076/âÂ 2403). Using the same methods, the luciferase reporter plasmids, pGL4 (âÂ 3825/âÂ 2403), pGL4 (âÂ 3391/âÂ 2403), pGL4 (âÂ 2849/âÂ 2403), pGL4 (âÂ 3288/âÂ 2403), pGL4 (âÂ 3020/âÂ 2403), pGL4 (âÂ 2935/âÂ 2403), pGL4 (âÂ 2897/âÂ 2403), pGL4 (âÂ 2897/âÂ 2495), pGL4 (âÂ 2897/âÂ 2583), pGL4 (âÂ 2897/âÂ 2672), pGL4 (âÂ 2897/âÂ 2743), and pGL4 (âÂ 2897/âÂ 2782) were generated. Different deletion fragments of SLC52A3-5â²FR (âÂ 3020/âÂ 2672) and luciferase reporter plasmids, pGL4 (ÎâÂ 2935/âÂ 2897), pGL4 (ÎâÂ 2897/âÂ 2849), pGL4 (ÎâÂ 2935/âÂ 2849), and pGL4 (ÎâÂ 2782/âÂ 2743), were constructed by GENEWIZ (Suzhou, China).</p>
      </sec>
      <sec id="Sec17">
        <title>Dual-luciferase reporter assay</title>
        <p id="Par30">Dual-luciferase reporter assay was performed as described previously [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. Briefly, KYSE150 or HEK293T Cells were seeded into 96-well plates at the density of 1Â ÃÂ 10<sup>4</sup> cells/well and cultured for 16â24Â h until grown to 70â90% confluence. They were then co-transfected with a firefly luciferase expressing plasmid (1Â Î¼g), and a renilla luciferase-expressing plasmid (20Â ng) (pRL-TK, Promega) as an internal control, using LIPOFECTAMINE 3000 Transfection Reagent (Thermo Fisher Scientific) in accordance with the manufacturerâs protocol. 48Â h later, cells were harvested using passive lysis buffer (Promega). Luciferase activity was analyzed using the GloMax 96 Microplate Luminometer (Promega). Values for each group are expressed as the meanÂ Â±Â standard deviation (SD) for three separate experiments.</p>
      </sec>
      <sec id="Sec18">
        <title>Western blot analysis</title>
        <p id="Par31">Whole cell protein extracts collected from cells were prepared in 1ÃÂ Laemmli Sample Buffer (Bio-Rad), nuclear cell protein extracts were isolated by NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Fisher Scientific), and membrane protein were isolated by Minute Plasma Membrane Protein Isolation Kit (Invent Biotechnologies, Inc.). The protein concentration was estimated by the Pierce 660Â nm Protein Assay (Thermo). An equal amount of tissues lysates was electrophoresed on 10% polyacrylamide gel using standard methodology. Then, the lysates were transferred to PVDF membranes (Roche). The membranes were blocked in blocking buffer for 1Â h followed by the addition of the primary antibody for 12Â h at 4Â Â°C. The membranes were then washed and incubated with a secondary antibody coupled to horseradish peroxidase for 1Â h at room temperature. Antigenâantibody complexes were detected by Western blot luminol reagent (Santa Cruz Biotechnology). The primary antibodies used are as follows, anti-IkkÎ±, anti-IkkÎ², anti-phospho-IkkÎ±/Î², anti-IÎºBÎ±, anti-phospho-IÎºBÎ±, anti-NF-ÎºB p65 and anti-phospho-NF-ÎºB p65 (ser536) (Cell Signaling Technology); anti-Rel-B, anti-NF-ÎºB p50, anti-SLC52A3, anti-Integrin-Î±5, anti-Lamin A/C, and anti-Î²-actin (Santa Cruz Biotechnology); anti-GAPDH (Sigma). Image acquisition and quantitative analysis were carried out using the ChemiDoc XRS imaging system (Bio-Rad).</p>
      </sec>
      <sec id="Sec19">
        <title>RNA extraction and quantitative real-time PCR</title>
        <p id="Par32">Total RNA was extracted from cells with TRIzol reagent (Invitrogen) in accordance with the manufacturerâs instructions. Reverse transcription (RT) and real-time PCR were performed as described earlier [<xref ref-type="bibr" rid="CR31">31</xref>]. Briefly, complementary DNA (cDNA) was generated from 1Â Î¼g total RNA in a final volume of 20Â Î¼L with Reverse Transcription System (TaKaRa). For the normalization of the amount of each transcript, the housekeeping gene ACTB (Î²-actin) was used as the internal control. The quantitative RT-PCR assay was carried out with the 7500 Real-Time PCR Systems system (Applied Biosystems) using SYBR Premix Ex Taq (TaKaRa) in accordance with the manufacturerâs instructions. Primers for quantitative RT-PCR are shown in Supplementary Table S3. The comparative deltaâdelta Ct (2<sup>âÎÎCT</sup>) method was used to calculate relative expression levels [<xref ref-type="bibr" rid="CR32">32</xref>].</p>
      </sec>
      <sec id="Sec20">
        <title>Chromatin immunoprecipitation</title>
        <p id="Par33">Chromatin immunoprecipitation (ChIP) analysis was performed using EZ-Magna ChIP A/G Chromatin Immunoprecipitation kit (Millipore) in accordance with the manufacturerâs instructions. Briefly, KYSE150 cells were seeded into 100Â mm cell culture dishes at the density of 1Â ÃÂ 10<sup>5</sup> cells per dish. Following formaldehyde crosslinking, cell lysate was sonicated on wet ice and then centrifuged to precipitate the debris. Input sample (5%) was collected before immunoprecipitation. Supernatant containing cross-linked chromatin was incubated overnight at 4Â Â°C with 1Â Î¼g of specific antibodies, including anti-STAT3 (Santa Cruz), anti-NF-ÎºB p65 (Santa Cruz), anti-Rel-B (Santa Cruz), anti-RNA polymerase II (Millipore), and normal mouse IgG (Millipore). After incubation, samples were subjected to DNA purification. Finally, purified DNA was analyzed by real-time PCR (qPCR) using <italic>SLC52A3</italic> 5â²-flanking region primers (Supplementary Table S3), according to procedures described previously [<xref ref-type="bibr" rid="CR27">27</xref>].</p>
      </sec>
      <sec id="Sec21">
        <title>Electrophoretic mobility shift assay</title>
        <p id="Par34">LightShift Chemiluminescent Electrophoretic mobility shift assay (EMSA) kit and Chemiluminescent Nucleic Acid Detection Module were purchased from Thermo Fisher Scientific. Purified biotin-labeled probes were synthesized from Sangon Biotech, Shanghai, China. The probe sequences were in the Supplementary Table S3. Nuclear extracts of KYSE150 cells were isolated by NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Fisher Scientific). For binding assays, 2Â Î¼g nuclear extracts were incubated with 20Â fmol probes at room temperature for 25Â min in 20Â Î¼L reaction buffers. Electrophoreses, transferring to a nylon membrane and crosslinking at high temperature (120Â Â°C), were performed in accordance with the manufacturerâs protocol. To confirm the specificity of the binding between transcription factors and the probes, antibodies anti-STAT3, anti-NF-ÎºB p65, anti-Rel-B (Santa Cruz), and 2Â Î¼g nuclear extracts were incubated for 10Â min at 4Â Â°C.</p>
      </sec>
      <sec id="Sec22">
        <title>Statistical analysis</title>
        <p id="Par35">Data analysis was performed using SPSS 16.0 software. A two-tailed independent sample <italic>t</italic> test was used to determine the significance of differences between groups. Differences were considered statistically significant at <italic>P</italic>Â &lt;Â 0.05 (*), <italic>P</italic>Â &lt;Â 0.01 (**), and <italic>P</italic>Â &lt;Â 0.01 (***). Data are plotted as meanÂ Â±Â SD.</p>
      </sec>
    </sec>
    <sec id="Sec23">
      <title>Results</title>
      <sec id="Sec24">
        <title>SLC52A3 protein was upregulated during the stepwise development of ESCC</title>
        <p id="Par36">The stepwise development from normal squamous epithelium to ESCC can be characterized by histologic analysis, from simple hyperplasia to low-grade and high-grade dysplasia, carcinoma in situ, and finally to invasive carcinoma. To investigate the alterations of SLC52A3 protein expression and their clinical significance during ESCC development, we first procured 39 ESCC individuals with most of whom having matched normal esophagus epithelium, simple hyperplasia, high-grade dysplasia, as well as ESCC samples. By immunohistochemical (IHC) staining, distinct SLC52A3 expression patterns were noted during stepwise ESCC developmental process. Specifically, normal esophagus epithelial cells were weakly positive for SLC52A3 signals. In contrast, distinctive nucleic staining of SLC52A3 was observed in simple hyperplasia of the esophagus. Notably, strong cytoplasmic and nucleic staining of SLC52A3 was detected in high-grade dysplasia, while diffuse cytoplasmic staining was observed in most of ESCC tissues (Fig.Â <xref rid="Fig1" ref-type="fig">1</xref>a, b). These data strongly imply the potential biological significance of SLC52A3 in ESCC. More importantly, these approaches identify SLC52A3 as a predictive biomarker for the development of ESCC.<fig id="Fig1"><label>Fig.Â 1</label><caption><p>Expression and prognostic significance of SLC52A3 in normal esophageal epithelium and ESCC. <bold>a</bold> Immunohistochemical staining of SLC52A3 during the process of transformation and development of ESCC. Scale bars, 50Â Î¼m. <bold>b</bold> Distribution of SLC52A3 expression in normal esophagus, simple (S) hyperplasia, high-grade (HG) dysplasia, and ESCC tissues. <bold>c</bold> Overall survivals of 246 patients with ESCC versus total SLC52A3 status. Higher SLC52A3 immunoreactivity in membrane and cytoplasm was associated with longer survival time of ESCC patients (<italic>P</italic>Â =Â 0.028). Higher SLC52A3 immunoreactivity in nucleus was associated with poor prognosis of ESCC patients (<italic>P</italic>Â =Â 0.017)</p></caption><graphic xlink:href="18_2018_2757_Fig1_HTML" id="MO1"/></fig>
</p>
        <p id="Par37">To further explore the clinical significance of the expression of SLC52A3 protein, we next performed IHC in a large independent cohort with 246 ESCC patients. Importantly, survival analysis revealed that SLC52A3 protein expression was a prognostic factor in ESCC. Specifically, stronger immunoreactivity of SLC52A3 in the membrane and cytoplasm was associated with a better survival (<italic>P</italic>Â =Â 0.028, Fig.Â <xref rid="Fig1" ref-type="fig">1</xref>c). In contrast, higher expression of SLC52A3 in nucleus was significantly associated with poor prognosis (<italic>P</italic>Â =Â 0.017, Fig.Â <xref rid="Fig1" ref-type="fig">1</xref>c).</p>
      </sec>
      <sec id="Sec25">
        <title>Identification of a novel SLC52A3 isoform in ESCC</title>
        <p id="Par38">Given the diversity of SLC52A3 expression in the ESCC tissue, we speculated that different transcription variants of SLC52A3 might exist. To test this, 5â²RACE experiments were performed using total RNA extracted from TE3 cells (an ESCC line). The results showed that <italic>SLC52A3</italic> gene had two different transcription initiation sites (TSSs), namely, TSS1 and TSS2 (Fig.Â <xref rid="Fig2" ref-type="fig">2</xref>a). These two TSSs were located at 2823 and 2726Â bp upstream from translational start codon, respectively. Notably, TSS2 contained intron 4. Compared with RefSeq databases, TSS1-initiated transcript corresponded to SLC52A3 mRNA (NM_033409.3), which here and after we named SLC52A3a. Thus, these results identified TSS2-initiated transcript as a novel alternative splicing isoform, which here and after we named SLC52A3b (Fig.Â <xref rid="Fig2" ref-type="fig">2</xref>b). The novel SLC52A3b isoform was confirmed by double restriction enzyme digestion (Fig.Â <xref rid="Fig2" ref-type="fig">2</xref>c). Sequence analysis also verified that SLC52A3b retained the 4th intron and premature termination. Data from the sequence analysis have been submitted to the GenBank database (SLC52A3a, GenBank accession No. KY978478; SLC52A3b, GenBank accession No. KY978479; also available in Supplementary Figure S1 and Figure S2).<fig id="Fig2"><label>Fig.Â 2</label><caption><p>Determination of the transcription start sites for the <italic>SLC52A3</italic> gene and identification of the SLC52A3 isoforms. <bold>a</bold> Identification of the transcription start sites (TSS) of the SLC52A3 transcripts using 5â²RACE analysis in KYSE150 cells. 5â²RACE experiments were repeated three times and a representative gel image is shown. Relative positioning of the oligonucleotide primers used for 5â²RACE amplification (up); amplification products by agarose electrophoresis and schematic of sequencing results (down). <bold>b</bold> mRNA schematic of SLC52A3a and SLC52A3b. <bold>c</bold> Full-length cDNA cloning and the double restriction enzyme digestion (<italic>Eco</italic>RI and <italic>Bam</italic>HI) of SLC52A3a and SLC52A3b. <bold>d</bold> Western blot analysis of GFP-tagged SLC52A3a and SLC52A3b transfected into KYSE150 cells. <bold>e</bold> Immunofluorescence analysis of SLC52A3a and SLC52A3b in KYSE150 cells. The GFP-tagged SLC52A3a and SLC52A3b were labeled with Alexa Fluor 488 (<italic>green</italic>) and nuclei were counterstained with DAPI (<italic>blue</italic>). <bold>f</bold> SLC52A3 was analyzed via western blot in cell lines and esophageal squamous cell carcinoma (ESCC) tissues, and Î²-actin was used as the internal control</p></caption><graphic xlink:href="18_2018_2757_Fig2_HTML" id="MO2"/></fig>
</p>
        <p id="Par39">This new SLC52A3b variant encodes a protein of 415 amino acids with predicted molecular mass of 45Â kDa. We next constructed GFP-tagged expression plasmids for SLC52A3a and SLC52A3b (Fig.Â <xref rid="Fig2" ref-type="fig">2</xref>d). Confocal immunofluorescence microscopy showed that the majority of SLC52A3a expressed in cell membrane and nucleus, while SLC52A3b localized in cell cytoplasm (Fig.Â <xref rid="Fig2" ref-type="fig">2</xref>e). We next measured endogenous SLC52A3 proteins in ESCC cell lines and primary tissues by Western blotting, and again, both isoforms were evident in ESCC cell lines (Fig.Â <xref rid="Fig2" ref-type="fig">2</xref>f). Notably, higher protein levels of SLC52A3a and SLC52A3b were also observed in ESCC tumor samples compared with matched normal tissues, in agreement with our earlier IHC results (Fig.Â <xref rid="Fig2" ref-type="fig">2</xref>f).</p>
      </sec>
      <sec id="Sec26">
        <title>High SLC52A3a nucleic expression correlates with poor prognosis in ESCC patients</title>
        <p id="Par40">To further explore the clinical significance of expression of SLC52A3a and SLC52A3a proteins, we first generated antibodies specifically recognizing different isoforms and confirmed their stringent specificity using recombinant SLC52A3 polypeptide by western blot (See Method). We next performed IHC in another large independent cohort with 290 ESCC patients. Importantly, stronger immunoreactivity of SLC52A3a in nucleus was significantly associated with poor prognosis of ESCC patients (<italic>P</italic>Â =Â 0.003), while its expression in cytoplasmic was not prognostic (<italic>P</italic>Â =Â 0.079) (Fig.Â <xref rid="Fig3" ref-type="fig">3</xref>a, b). On the contrary, heightened expression of SLC52A3b (cytoplasm) was significantly associated with favorable prognosis of ESCC patients (<italic>P</italic>Â =Â 0.026) (Fig.Â <xref rid="Fig3" ref-type="fig">3</xref>c, d). These data strongly suggest distinct functions of the two isoforms in the biology of ESCC cells.<fig id="Fig3"><label>Fig.Â 3</label><caption><p>Expression and prognostic significance of SLC52A3a and SLC52A3b in ESCC. <bold>a</bold> SLC52A3a expression was detected by IHC in 290 ESCC samples. Cytoplasmic and nuclear staining of SLC52A3a were observed. Scale bars, 50Â Î¼m. <bold>b</bold> SLC52A3a expression in cytoplasmic was not associated with survival time of ESCC patients (<italic>P</italic>Â =Â 0.079). Higher SLC52A3a immunoreactivity in nucleus was associated with poor prognosis of ESCC patients (<italic>P</italic>Â =Â 0.003). <bold>c</bold> SLC52A3b expression was detected by IHC in 290 ESCC samples. Cytoplasmic staining of SLC52A3b was observed. Scale bars, 50Â Î¼m. <bold>d</bold> Higher SLC52A3b immunoreactivity in cytoplasmic was associated with poor prognosis of ESCC patients (<italic>P</italic>Â =Â 0.026)</p></caption><graphic xlink:href="18_2018_2757_Fig3_HTML" id="MO3"/></fig>
</p>
      </sec>
      <sec id="Sec27">
        <title>Functional roles of SLC52A3 in ESCC</title>
        <p id="Par41">We examined the sub-cellular localization of SLC52A3 in HEK293T, KYSE150, and KYSE180 cells. Confocal microscopy showed that SLC52A3 was detectable in all sub-cellular compartments, including cell membrane, cytoplasm, as well as nucleus (Fig.Â <xref rid="Fig4" ref-type="fig">4</xref>a). Next, upon cell fractionation, western blotting verified that SLC52A3a expressed in cell membrane, cytoplasm, and nucleus, while the majority of SLC52A3b expressed in cell cytoplasm (Fig.Â <xref rid="Fig4" ref-type="fig">4</xref>b). These results were concordance with the findings from IHC assays in primary ESCC tissues.<fig id="Fig4"><label>Fig.Â 4</label><caption><p>Localization and function of SLC52A3 in human ESCC cells. <bold>a</bold> Immunofluorescence analysis of SLC52A3 in HEK293T, KYSE150, and KYSE180 cells. The target protein and nuclei were labeled, respectively, with Dylight594 (red) and DAPI (blue). <bold>b</bold> Sub-cellular fractionations of HEK293T and KYSE150 cells were made as described in Materials and Methods. The fractions were analyzed with anti-SLC52A3, anti-Integrin Î±5 as membrane, anti-Lamin A/C as nuclear, and anti-GAPDH as cytoplasmic marker antibody. Shown are representative data of two independent experiments. <bold>c</bold> SLC52A3 ablation in KYSE180 and SHEEC cells was confirmed by Western blot analysis (left). MTS assay of KYSE180 and SHEEC cells after SLC52A3 knockdown (right). Experiments were repeated three times with similar results. <bold>d</bold> shRNA lentivirus-mediated SLC52A3 knockdown KYSE180 and SHEEC cells showed a significantly reduced colony formation compared with control cells. Representative pictures (top) and quantitative analyses (bottom) of colony numbers. Data show representative colony formation assay for each condition performed in triplicateÂ Â±Â SD, for three independent experiments. <bold>e</bold> KYSE150 and KYSE180 cells were overexpression with SLC52A3a or SLC52A3b by adenovirus-mediated. The efficiency of SLC52A3a or SLC52A3b overexpression was evaluated using real-time RT-PCR (top). MTS assay of KYSE150 and KYSE180 cells after SLC52A3a or SLC52A3b overexpression (bottom). Experiments were repeated three times with similar results. Error bars indicate SD. *<italic>P</italic>Â &lt;Â 0.05, **<italic>P</italic>Â &lt;Â 0.01 based on Studentâs <italic>t</italic> tests</p></caption><graphic xlink:href="18_2018_2757_Fig4_HTML" id="MO4"/></fig>
</p>
        <p id="Par42">We next sought to investigate the biological functions of SLC52A3 using ESCC cell line models. First, we determined the transport capacity of riboflavin by either SLC52A3a or SLC52A3b in KYSE150 and KYSE510 cells by measuring both riboflavin consumption in cell culture medium and intracellular riboflavin concentration using high-performance liquid chromatography (HPLC). Importantly, our results showed that cells expressing SLC52A3a exhibited faster riboflavin consumption and maintained higher intracellular concentration of riboflavin compared to control cells. In contrast, expression of SLC52A3b did not cause any alterations in either riboflavin consumption or intracellular riboflavin concentration (Supplementary Figure S3), suggesting that SLC52A3a has higher capacity in transporting riboflavin than SLC52A3b. Importantly, shRNA-mediated knockdown of SLC52A3 (shSLC52A3-6#) markedly decreased the proliferation of both KYSE180 and SHEEC cells (Fig.â<xref rid="Fig4" ref-type="fig">4</xref>c). ESCC colony formation was also potently inhibited upon silencing of SLC52A3 (Fig.â<xref rid="Fig4" ref-type="fig">4</xref>d). We next ectopically expressed either isoforms, and noted that overexpression of SLC52A3a significantly increased the proliferation of both KYSE150 and KYSE180 cells. In contrast, overexpression of SLC52A3b did not produce the same effect. These data together suggest that isoform SLC52A3a, but not SLC52A3b, promotes the malignant phenotype of ESCC cells (Fig.â<xref rid="Fig4" ref-type="fig">4</xref>e).</p>
      </sec>
      <sec id="Sec28">
        <title>Identification of transcriptional regulatory elements in <italic>SLC52A3</italic> 5â²-flanking regions</title>
        <p id="Par43">We next probed the mechanisms underlying the upregulation of SLC52A3 expression in ESCC. To identify its transcriptional regulatory elements, a series of <italic>SLC52A3</italic> 5â²-flanking regions (spanning âÂ 5076/âÂ 2403 upstream of translational starting codon) were cloned into reporter gene constructs. The âÂ 5076/âÂ 2403 region of <italic>SLC52A3</italic> exhibited maximum luciferase activity, and sequence deletion from nt âÂ 3391 to nt âÂ 2849 led to anÂ ~Â 80% reduction in luciferase activity (Fig.Â <xref rid="Fig5" ref-type="fig">5</xref>a). We thus continued to fine-map this region by further serial deletions. Importantly, both deletions of âÂ 2935/âÂ 2897 and âÂ 2897/âÂ 2849 markedly decreased the reporter activity in KYSE150 cells, while only the deletion of âÂ 2897/âÂ 2849 strongly decreased the activity in HEK293T cells (Fig.Â <xref rid="Fig5" ref-type="fig">5</xref>b). These data suggest that region âÂ 2897/âÂ 2849 operates as the basic (nontissue-specific) regulatory element of <italic>SLC52A3</italic>, and region âÂ 2935/âÂ 2897 might be an ESCC specific regulatory element.<fig id="Fig5"><label>Fig.Â 5</label><caption><p>Transcriptional regulatory region of the human <italic>SLC52A3</italic> 5â²-flanking region âÂ 5076/âÂ 2403. Localization of the transcriptional regulatory region of human <italic>SLC52A3</italic> by 5â²-deletion analysis <bold>a</bold>, <bold>b</bold> Schematic representation of the <italic>SLC52A3</italic> 5â²-flanking region constructs used for transient transfections is shown in the left. 5â²-Deletion constructs were co-transfected with pRL-TK into KYSE150 and HEK293T cells. Luciferase activity (right) was normalized to Renilla luciferase activity and then shown relative to that of cells transfected with pGL4-hS (âÂ 5076/âÂ 2403) (<bold>a</bold>) or pGL4-hS (âÂ 3391/âÂ 2403) (<bold>b</bold>), which were set to 100%. Localization of the transcriptional regulatory region of human <italic>SLC52A3</italic> by 3â²-deletion analysis (<bold>c</bold>, <bold>d</bold>) and fragments deletion analysis (<bold>f</bold>) in KYSE150 cells. <bold>e</bold> Schematic of SLC52A3 5â²-flanking region transcriptional regulatory elements (TBS1-5). Luciferase activity was normalized to Renilla luciferase activity and then shown relative to that of cells transfected with pGL4 (âÂ 2897/âÂ 2403) (<bold>c</bold>), pGL4 (âÂ 2849/âÂ 2403) (<bold>d</bold>) or pGL4 (âÂ 3020/âÂ 2672) (<bold>f</bold>), which were set to 100%. Each value represents the meanÂ Â±Â SD. The data are representative of at least two independent experiments. Transfections were carried out in six times repeated for each experiment (<italic>n</italic>Â =Â 6). **<italic>P</italic>Â &lt;Â 0.01; ***<italic>P</italic>Â &lt;Â 0.001</p></caption><graphic xlink:href="18_2018_2757_Fig5_HTML" id="MO5"/></fig>
</p>
        <p id="Par44">To further investigate the transcriptional regulatory elements of <italic>SLC52A3</italic>, a series of 5â²-flanking regions spanning âÂ 3020/âÂ 2403 were studies by progressive 3â²-deletions, which initially increased the reporter activity and then followed by decreases. Specifically, deletion from nt âÂ 2403 to nt âÂ 2495 caused a 16-fold increase in luciferase activity, whereas deletion from âÂ 2583/âÂ 2672, âÂ 2672/âÂ 2743, and âÂ 2743/âÂ 2782 markedly decreased the activity (Fig.Â <xref rid="Fig5" ref-type="fig">5</xref>c, d). This result indicated that 5â²-flanking regions of <italic>SLC52A3</italic> gene contained at least five transcriptional regulatory elements, namely TBS1âTBS5, as illustrated in Fig.Â <xref rid="Fig5" ref-type="fig">5</xref>e.</p>
        <p id="Par45">Further progressive deletions of either TBS1, TBS2, or both TBS1/TBS2 did not alter the reporter activity. However, the deletion of TBS3 sharply and significantly reduced reporter activity (Fig.Â <xref rid="Fig5" ref-type="fig">5</xref>f), suggesting that a key cis-acting element exists in this segment (âÂ 2782/âÂ 2743) which regulates <italic>SLC52A3</italic> transcription in ESCC cells.</p>
      </sec>
      <sec id="Sec29">
        <title>NF-ÎºB p65/Rel-B factor binds to the NF-ÎºB-binding site within TBS3 and activates SLC52A3 transcription</title>
        <p id="Par46">The above data prompted us to further investigate transcription factor-binding sites within TBS3. Thus, we subjected this genomic region to different motif analysis methods (Fig.Â <xref rid="Fig6" ref-type="fig">6</xref>a), and identified binding motifs for NF-ÎºB p65/Rel-B (âÂ 2760/âÂ 2750, underlined) and STAT3 (âÂ 2755/âÂ 2745, italic). We then performed ChIP analysis to test the prediction. Immunoprecipitated chromosomal DNA was subjected to semi-quantitative PCR agarose gel electrophoresis and qPCR analysis (anti-RNA polymerase II and normal mouse IgG were used as a positive control and negative control, respectively). Importantly, NF-ÎºB p65 and Rel-B, indeed, bound to this region, whereas STAT3 did not (Fig.Â <xref rid="Fig6" ref-type="fig">6</xref>b). To assess the specificity of NF-ÎºB p65/Rel-B binding, nuclear extracts of KYSE150 cells were incubated with a biotinylated oligonucleotide containing the NF-ÎºB p65/Rel-B and STAT3 motif sequences within TBS3. Signals in EMSA results showed that, compared with the nuclear extract and probe control (Fig.Â <xref rid="Fig6" ref-type="fig">6</xref>c, lane 2), either anti-NF-ÎºB p65 or anti-Rel-B antibody generated super-shift complexes, which was not formed by anti-STAT3 antibody (Fig.Â <xref rid="Fig6" ref-type="fig">6</xref>c, lane 3, 4 and 5). These results together confirmed that NF-ÎºB p65 and Rel-B bound to NF-ÎºB-binding motif (from nt âÂ 2760 to nt âÂ 2750) within TBS3 element of <italic>SLC52A3</italic> 5â²-flanking region.<fig id="Fig6"><label>Fig.Â 6</label><caption><p>Transcription factors NF-ÎºB p65/Rel-B binds to the NF-ÎºB-binding site within the âÂ 2782/âÂ 2743 fragment of the <italic>SLC52A3</italic> 5â²-flanking region and TNFÎ±-triggered NF-ÎºB-cell signaling upregulates transcriptional expression of human SLC52A3. <bold>a</bold> Bioinformatics analysis of regulatory elements in <italic>SLC52A3</italic> 5â²-flanking region. Transcription factors prediction of 5â²-flanking region TBS3 (âÂ 2782/âÂ 2743) by Alibaba 2.1 and JASPAR. NF-ÎºB p65/Rel-B-binding site: underline; STAT3 binding site: italic. <bold>b</bold> ChIP-qPCR analysis of STAT3, NF-ÎºB p65 and Rel-B in immunoprecipitated DNA fragments on <italic>SLC52A3</italic> 5â²-flanking region. Semi-quantitative PCR agarose gel electrophoresis (<italic>left</italic>) and quantitative PCR (<italic>right</italic>) results were showed. anti-RNA polymerase II was used as a positive control and normal mouse IgG was used as a negative control. Data are normalized to total input DNA and expressed as meanÂ Â±Â SD of three independent samples. ***<italic>P</italic>Â &lt;Â 0.001. <bold>c</bold> EMSA assay of the nuclear extract prepared from KYSE150 cells bound to the sequence of âÂ 2849/âÂ 2743 fragment within the <italic>SLC52A3</italic> 5â²-flanking region. Lane 1 was loaded only with the nuclear extract; lane 2 was loaded with the biotin-labeled probe and nuclear extract; lanes 3, 4, 5 were loaded with the biotin-labeled probe, nuclear extract, and antibody (anti-STAT3, anti-NF-ÎºB p65 or anti-Rel-B). <bold>d</bold> Expression of NF-ÎºB-cell signaling proteins and SLC52A3 was evaluated using western blot analysis in various concentrations and times TNFÎ±-treated KYSE150 and KYSE510 cells. <bold>e</bold> KYSE150 cells were pretreated with QNZ (500Â nM) or JSH-23 (300Â nM) for 24Â h, followed by TNFÎ± (20Â ng/mL) treatment for 6Â h. The expression of SLC52A3 mRNA was evaluated using qRT-PCR. The data are representative of three independent experiments. <bold>f</bold> KYSE150 cells were treated as described above, and cell lysis was quantified and subjected to western blot to detect NF-ÎºB-cell signaling proteins and SLC52A3 activation. Blots are representative of three independent experiments. <bold>g</bold> Dual-luciferase reporter assay <italic>SLC52A3</italic> 5â²-flanking region (âÂ 3020/âÂ 2672) (up) and (âÂ 2849/âÂ 2672) (down) activity by 3â²-deletion or fragments deletion in KYSE150 cells with or without TNFÎ± treated, pGL4.32[luc2P/NF-ÎºB-RE] (Promega) as the positive control. The data are representative of at least two independent experiments. Transfections were carried out in six times repeated for each experiment (<italic>n</italic>Â =Â 6). *<italic>P</italic>Â &lt;Â 0.05; **<italic>P</italic>Â &lt;Â 0.01; ***<italic>P</italic>Â &lt;Â 0.001</p></caption><graphic xlink:href="18_2018_2757_Fig6_HTML" id="MO6"/></fig>
</p>
        <p id="Par47">NF-ÎºB family members modulate the transcription of a number of genes that regulate inflammation, apoptosis, and tumorigenesis [<xref ref-type="bibr" rid="CR33">33</xref>â<xref ref-type="bibr" rid="CR36">36</xref>]. Tumor necrosis factor Î± (TNFÎ±) is among the best-characterized activators upstream of NF-ÎºB signaling pathway [<xref ref-type="bibr" rid="CR37">37</xref>]. To explore whether NF-ÎºB p65/Rel-B regulate the transcription of SLC52A3, KYSE150, and KYSE510 cell lines were treated with various concentrations of TNFÎ±. As expected, TNFÎ± stimulation increased NF-ÎºB activity, as evident by the enhanced phosphorylation of IKKÎ±/Î², as well as increased expression of Rel-B and p50. Notably, activation of NF-ÎºB pathway resulted in strong upregulation of SLC52A3 expression, particularly SLC52A3a (Fig.Â <xref rid="Fig6" ref-type="fig">6</xref>d). On the other hand, treatment of NF-ÎºB inhibitors QNZ or JSH-23 substantially decreased the expression levels of SLC52A3a and SLC52A3b (Fig.Â <xref rid="Fig6" ref-type="fig">6</xref>e). NF-ÎºB signaling pathway-related proteins and SLC52A3, specially SLC52A3a, were also decreased in KYSE150 cells (Fig.Â <xref rid="Fig6" ref-type="fig">6</xref>f).</p>
        <p id="Par48">To further confirm the transcriptional regulation of NF-ÎºB on TBS3 segment, we performed progressive deletions for reporter luciferase assay under the treatment of TNFÎ±. Importantly, TNFÎ± stimulated the reporter activity of all constructs except for the one without NF-ÎºB-binding sequences (Fig.Â <xref rid="Fig6" ref-type="fig">6</xref>g, upper panel). Similar results were obtained by serial 3â² deletions (Fig.Â <xref rid="Fig6" ref-type="fig">6</xref>g, lower panel). These results together suggest that NF-ÎºB signaling activates SLC52A3 transcription through direct binding to its canonical sequences within <italic>SLC52A3</italic> 5â²-flanking region.</p>
      </sec>
    </sec>
    <sec id="Sec30">
      <title>Discussion</title>
      <p id="Par49">Recent results demonstrated profound epigenomic dysregulation of ESCC transcriptomes [<xref ref-type="bibr" rid="CR38">38</xref>â<xref ref-type="bibr" rid="CR41">41</xref>]. In the present study, we found that SLC52A3 was transcriptionally upregulated in both esophagus dysplasia and ESCC, and high nucleus expression of SLC52A3 was correlated with poor prognosis. Importantly, SLC52A3 promoted cell proliferation and colony formation in ESCC. Our results further showed that SLC52A3 had two transcript variants that differ in their transcriptional start sites (TSS) and encoded two different proteins. The previous studies reported that intron retention may be ascribed to the dysfunction of splicing factors or weaker splice sites [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]. However, whether alternative transcription start site and splicing are functionally linked remains unclear. Further investigations are thus warranted in the future.</p>
      <p id="Par50">A previous study reported the minimal promoter of <italic>SLC52A3</italic> [<xref ref-type="bibr" rid="CR44">44</xref>], which were in agreement with our data. We here, however, identified an additional TSS of <italic>SLC52A3</italic> using RACE. Luciferase reporter assay revealed that 5â²-flanking regions of <italic>SLC52A3</italic> contain at least five transcriptional regulatory elements (TBS1âTBS5). Furthermore, our results revealed and validated a functional-binding site for NF-ÎºB p65/Rel-B within TBS3. Interestingly, the previous GWAS results showed that an SNP locus rs13042395 (C&gt;T), located âÂ 8093 nt upstream of <italic>SLC52A3</italic> TSS, was associated with increased ESCC risk [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. A study demonstrated that the CC genotype of this SNP conferred stronger transcription activity for <italic>SLC52A3</italic> [<xref ref-type="bibr" rid="CR47">47</xref>]. Together with our results, these findings suggest a complex regulatory mechanism controlling SLC52A3 transcription in ESCC.</p>
      <p id="Par51">Recently, multiple studies highlighted the pro-inflammatory effects of low concentration of riboflavin [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR48">48</xref>â<xref ref-type="bibr" rid="CR50">50</xref>], presumably resulting in the release of a number of cytokines, which in turn causes the activation of NF-ÎºB. NF-ÎºB p65 is upregulated in ESCC tissues, and its hyper-activation plays a role in the occurrence, development and metastasis of ESCC [<xref ref-type="bibr" rid="CR51">51</xref>â<xref ref-type="bibr" rid="CR53">53</xref>]. The present study found that TNFÎ± induced overexpression of SLC52A3 in ESCC cells by activating NF-ÎºB signaling (Fig.Â <xref rid="Fig7" ref-type="fig">7</xref>). We speculate that the riboflavin deficiency in ESCC cells increases TNFÎ± and activates NF-ÎºB, which increases the expression of SLC52A3, providing a mechanistic explanation for the negative feedback regulatory mechanisms maintaining riboflavin homeostasis inferred from the previous studies [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR54">54</xref>].<fig id="Fig7"><label>Fig.Â 7</label><caption><p>Schematic model of the NF-ÎºB pathway in the regulation of the human SLC52A3 transactivation. Environmental stimuli that activate NF-ÎºB p65/Rel-B cause phosphorylation of IÎºB, which is followed by its ubiquitination and subsequent degradation. This results in the exposure of the nuclear localization signals (NLS) on NF-ÎºB p65/Rel-B subunits and the subsequent translocation of the molecule to the nucleus. In the nucleus, NF-ÎºB p65/Rel-B bind to their consensus sequence in the human SLC52A3, resulting in SLC52A3 transcriptional activation</p></caption><graphic xlink:href="18_2018_2757_Fig7_HTML" id="MO7"/></fig>
</p>
      <p id="Par52">In conclusion, our findings establish the clinical significance of SLC52A3 expression in the pathogenesis of ESCC, and highlight both the predictive and prognostic values of this pro-growth protein. We further identified isoform-specific functions of SLC52A3, in which SLC52A3a, but not SLC52A3b, promotes the malignant phenotypes of ESCC cells. Mechanistically, we reveal a direct transcription regulation of NF-ÎºB p65/Rel-B on the expression of SLC52A3, providing important insights into the tumorigenesis and progression of ESCC.
</p>
    </sec>
    <sec sec-type="supplementary-material">
      <title>Electronic supplementary material</title>
      <sec id="Sec31">
        <p>Below is the link to the electronic supplementary material.
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="18_2018_2757_MOESM1_ESM.docx"><caption><p>Supplementary material 1 (DOCX 173Â kb)</p></caption></media></supplementary-material></p>
      </sec>
    </sec>
  </body>
  <back>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>ChIP</term>
          <def>
            <p id="Par2">Chromatin immunoprecipitation</p>
          </def>
        </def-item>
        <def-item>
          <term>EMSA</term>
          <def>
            <p id="Par3">Electrophoretic mobility shift assay</p>
          </def>
        </def-item>
        <def-item>
          <term>ESCC</term>
          <def>
            <p id="Par4">Esophageal squamous cell carcinoma</p>
          </def>
        </def-item>
        <def-item>
          <term>FR</term>
          <def>
            <p id="Par5">Flanking regions</p>
          </def>
        </def-item>
        <def-item>
          <term>RACE</term>
          <def>
            <p id="Par6">Rapid amplification of cDNA ends</p>
          </def>
        </def-item>
        <def-item>
          <term>RT-PCR</term>
          <def>
            <p id="Par7">Reverse transcriptase polymerase chain reaction</p>
          </def>
        </def-item>
        <def-item>
          <term>TRADD</term>
          <def>
            <p id="Par8">TNF receptor death domain</p>
          </def>
        </def-item>
        <def-item>
          <term>TSS</term>
          <def>
            <p id="Par9">Transcriptional start site</p>
          </def>
        </def-item>
        <def-item>
          <term>PBS</term>
          <def>
            <p id="Par10">Phosphate buffer saline</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <fn-group>
      <fn>
        <p>
          <bold>Electronic supplementary material</bold>
        </p>
        <p>The online version of this article (10.1007/s00018-018-2757-4) contains supplementary material, which is available to authorized users.</p>
      </fn>
    </fn-group>
    <ack>
      <title>Acknowledgements</title>
      <p>This work was supported by a grant from the Natural Science Foundation of China-Guangdong Joint Fund (No. U1301227 and No. U1601229), the National Cohort of Esophageal Cancer of China (No. 2016YFC0901400), the National Natural Science Foundation of China (No. 81772532 and No. 81472613), and the Department of Education, Guangdong Government under the Top-tier University Development Scheme for Research and Control of Infectious Diseases. Lin DC was supported by the National Natural Science Foundation of China (81672786). We are grateful for assistance from the Central Laboratory at Shantou University Medical College, including Wen-Hong Luo and Hong-Jun Luo, for obtaining the riboflavin concentrations data by HPLC.</p>
    </ack>
    <notes notes-type="author-contribution">
      <title>Author contributions</title>
      <p>LL: data collection, data analysis, interpretation, and drafting; LYX, EML, DCL, and LDW: study design, study supervision, and final approval of the manuscript; XXP, XEX, and JZH: Tissue microarrays construction and immunohistochemical staining; JYW and ZYW: sample collection and follow-up; FL and JSZ: dual-luciferase reporter assay; WW: DNA cloning and confocal microscope; LDL: cell culture.</p>
    </notes>
    <notes notes-type="COI-statement">
      <title>Compliance with ethical standards</title>
      <sec id="FPar1">
        <title>Conflict of interest</title>
        <p id="Par53">The authors declare that they have no conflicts of interest with the contents of this article.</p>
      </sec>
    </notes>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Zheng</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Zeng</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>He</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Annual report on status of cancer in China, 2011</article-title>
          <source>Chin J Cancer Res</source>
          <year>2015</year>
          <volume>27</volume>
          <issue>1</issue>
          <fpage>2</fpage>
          <lpage>12</lpage>
          <pub-id pub-id-type="doi">10.1186/s40880-015-0001-2</pub-id>
          <?supplied-pmid 25717220?>
          <pub-id pub-id-type="pmid">25717220</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thurnham</surname>
              <given-names>DI</given-names>
            </name>
            <name>
              <surname>Rathakette</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Hambidge</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Munoz</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Crespi</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Riboflavin, vitamin A and zinc status in Chinese subjects in a high-risk area for oesophageal cancer in China</article-title>
          <source>Hum Nutr Clin Nutr</source>
          <year>1982</year>
          <volume>36</volume>
          <issue>5</issue>
          <fpage>337</fpage>
          <lpage>349</lpage>
          <?supplied-pmid 7174357?>
          <pub-id pub-id-type="pmid">7174357</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yang</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Miao</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Xue</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>You</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lu</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Diet and vitamin nutrition of the high esophageal cancer risk population in Linxian, China</article-title>
          <source>Nutr Cancer</source>
          <year>1982</year>
          <volume>4</volume>
          <issue>2</issue>
          <fpage>154</fpage>
          <lpage>164</lpage>
          <pub-id pub-id-type="doi">10.1080/01635588209513751</pub-id>
          <?supplied-pmid 7162996?>
          <pub-id pub-id-type="pmid">7162996</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yang</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Sun</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>QU</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>KW</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>GY</given-names>
            </name>
            <name>
              <surname>Zheng</surname>
              <given-names>SF</given-names>
            </name>
            <name>
              <surname>Ershow</surname>
              <given-names>AG</given-names>
            </name>
            <name>
              <surname>Blot</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>JY</given-names>
            </name>
          </person-group>
          <article-title>Vitamin A and other deficiencies in Linxian, a high esophageal cancer incidence area in northern China</article-title>
          <source>J Natl Cancer Inst</source>
          <year>1984</year>
          <volume>73</volume>
          <issue>6</issue>
          <fpage>1449</fpage>
          <lpage>1453</lpage>
          <?supplied-pmid 6595453?>
          <pub-id pub-id-type="pmid">6595453</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Groenewald</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Langenhoven</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Beyers</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>du Plessis</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Ferreira</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>van Rensburg</surname>
              <given-names>SJ</given-names>
            </name>
          </person-group>
          <article-title>Nutrient intakes among rural Transkeians at risk for oesophageal cancer</article-title>
          <source>South Afr Med J</source>
          <year>1981</year>
          <volume>60</volume>
          <issue>25</issue>
          <fpage>964</fpage>
          <lpage>967</lpage>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Siassi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Ghadirian</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Riboflavin deficiency and esophageal cancer: a case control-household study in the Caspian Littoral of Iran</article-title>
          <source>Cancer Detect Prev</source>
          <year>2005</year>
          <volume>29</volume>
          <issue>5</issue>
          <fpage>464</fpage>
          <lpage>469</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cdp.2005.08.001</pub-id>
          <?supplied-pmid 16183212?>
          <pub-id pub-id-type="pmid">16183212</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Khan</surname>
              <given-names>NA</given-names>
            </name>
            <name>
              <surname>Teli</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Mohib-Ul Haq</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bhat</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Lone</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Afroz</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>A survey of risk factors in carcinoma esophagus in the valley of Kashmir, Northern India</article-title>
          <source>J Cancer Res Ther</source>
          <year>2011</year>
          <volume>7</volume>
          <issue>1</issue>
          <fpage>15</fpage>
          <lpage>18</lpage>
          <pub-id pub-id-type="doi">10.4103/0973-1482.80431</pub-id>
          <?supplied-pmid 21546736?>
          <pub-id pub-id-type="pmid">21546736</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Zempleni</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Low activity of LSD1 elicits a pro-inflammatory gene expression profile in riboflavin-deficient human T lymphoma Jurkat cells</article-title>
          <source>Genes Nutr</source>
          <year>2014</year>
          <volume>9</volume>
          <issue>5</issue>
          <fpage>422</fpage>
          <pub-id pub-id-type="doi">10.1007/s12263-014-0422-6</pub-id>
          <?supplied-pmid 25103574?>
          <pub-id pub-id-type="pmid">25103574</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mazur-Bialy</surname>
              <given-names>AI</given-names>
            </name>
            <name>
              <surname>Pochec</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Plytycz</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Immunomodulatory effect of riboflavin deficiency and enrichmentâreversible pathological response versus silencing of inflammatory activation</article-title>
          <source>J Physiol Pharmacol</source>
          <year>2015</year>
          <volume>66</volume>
          <issue>6</issue>
          <fpage>793</fpage>
          <lpage>802</lpage>
          <?supplied-pmid 26769828?>
          <pub-id pub-id-type="pmid">26769828</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cobianchi</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Fornoni</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Pileggi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Molano</surname>
              <given-names>RD</given-names>
            </name>
            <name>
              <surname>Sanabria</surname>
              <given-names>NY</given-names>
            </name>
            <name>
              <surname>Gonzalez-Quintana</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Bocca</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Marzorati</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Zahr</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Hogan</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Ricordi</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Inverardi</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Riboflavin inhibits IL-6 expression and p38 activation in islet cells</article-title>
          <source>Cell Transplant</source>
          <year>2008</year>
          <volume>17</volume>
          <issue>5</issue>
          <fpage>559</fpage>
          <lpage>566</lpage>
          <pub-id pub-id-type="doi">10.3727/096368908785096060</pub-id>
          <?supplied-pmid 18714675?>
          <pub-id pub-id-type="pmid">18714675</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Iwanaga</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Hasegawa</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hultquist</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Harada</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Yoshikawa</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Yanamadala</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Liao</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Visovatti</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Pinsky</surname>
              <given-names>DJ</given-names>
            </name>
          </person-group>
          <article-title>Riboflavin-mediated reduction of oxidant injury, rejection, and vasculopathy after cardiac allotransplantation</article-title>
          <source>Transplantation</source>
          <year>2007</year>
          <volume>83</volume>
          <issue>6</issue>
          <fpage>747</fpage>
          <lpage>753</lpage>
          <pub-id pub-id-type="doi">10.1097/01.tp.0000256283.06469.d4</pub-id>
          <?supplied-pmid 17414708?>
          <pub-id pub-id-type="pmid">17414708</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yamamoto</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Inoue</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ohta</surname>
              <given-names>KY</given-names>
            </name>
            <name>
              <surname>Fukatsu</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Maeda</surname>
              <given-names>JY</given-names>
            </name>
            <name>
              <surname>Yoshida</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Yuasa</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Identification and functional characterization of rat riboflavin transporter 2</article-title>
          <source>J Biochem</source>
          <year>2009</year>
          <volume>145</volume>
          <issue>4</issue>
          <fpage>437</fpage>
          <lpage>443</lpage>
          <pub-id pub-id-type="doi">10.1093/jb/mvn181</pub-id>
          <?supplied-pmid 19122205?>
          <pub-id pub-id-type="pmid">19122205</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fujimura</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Yamamoto</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Murata</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Yasujima</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Inoue</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ohta</surname>
              <given-names>KY</given-names>
            </name>
            <name>
              <surname>Yuasa</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Functional characteristics of the human ortholog of riboflavin transporter 2 and riboflavin-responsive expression of its rat ortholog in the small intestine indicate its involvement in riboflavin absorption</article-title>
          <source>J Nutr</source>
          <year>2010</year>
          <volume>140</volume>
          <issue>10</issue>
          <fpage>1722</fpage>
          <lpage>1727</lpage>
          <pub-id pub-id-type="doi">10.3945/jn.110.128330</pub-id>
          <?supplied-pmid 20724488?>
          <pub-id pub-id-type="pmid">20724488</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bowman</surname>
              <given-names>BB</given-names>
            </name>
            <name>
              <surname>McCormick</surname>
              <given-names>DB</given-names>
            </name>
            <name>
              <surname>Rosenberg</surname>
              <given-names>IH</given-names>
            </name>
          </person-group>
          <article-title>Epithelial transport of water-soluble vitamins</article-title>
          <source>Annu Rev Nutr</source>
          <year>1989</year>
          <volume>9</volume>
          <issue>1</issue>
          <fpage>187</fpage>
          <lpage>199</lpage>
          <pub-id pub-id-type="doi">10.1146/annurev.nu.09.070189.001155</pub-id>
          <?supplied-pmid 2669869?>
          <pub-id pub-id-type="pmid">2669869</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yao</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Yonezawa</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Yoshimatsu</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Masuda</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Katsura</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Inui</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Identification and comparative functional characterization of a new human riboflavin transporter hRFT3 expressed in the brain</article-title>
          <source>J Nutr</source>
          <year>2010</year>
          <volume>140</volume>
          <issue>7</issue>
          <fpage>1220</fpage>
          <lpage>1226</lpage>
          <pub-id pub-id-type="doi">10.3945/jn.110.122911</pub-id>
          <?supplied-pmid 20463145?>
          <pub-id pub-id-type="pmid">20463145</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Subramanian</surname>
              <given-names>VS</given-names>
            </name>
            <name>
              <surname>Ghosal</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kapadia</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Nabokina</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Said</surname>
              <given-names>HM</given-names>
            </name>
          </person-group>
          <article-title>Molecular mechanisms mediating the adaptive regulation of intestinal riboflavin uptake process</article-title>
          <source>PLoS One</source>
          <year>2015</year>
          <volume>10</volume>
          <issue>6</issue>
          <fpage>e0131698</fpage>
          <pub-id pub-id-type="doi">10.1371/journal.pone.0131698</pub-id>
          <?supplied-pmid 26121134?>
          <pub-id pub-id-type="pmid">26121134</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aili</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hasim</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kelimu</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Guo</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Mamtimin</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Abudula</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Upur</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Association of the plasma and tissue riboflavin levels with C20orf54 expression in cervical lesions and its relationship to HPV16 infection</article-title>
          <source>PLoS One</source>
          <year>2013</year>
          <volume>8</volume>
          <issue>11</issue>
          <fpage>e79937</fpage>
          <pub-id pub-id-type="doi">10.1371/journal.pone.0079937</pub-id>
          <?supplied-pmid 24260322?>
          <pub-id pub-id-type="pmid">24260322</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Eli</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>DS</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>WW</given-names>
            </name>
            <name>
              <surname>Kong</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Du</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Wumar</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mamtimin</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Sheyhidin</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Hasim</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Decreased blood riboflavin levels are correlated with defective expression of RFT2 gene in gastric cancer</article-title>
          <source>World J Gastroenterol</source>
          <year>2012</year>
          <volume>18</volume>
          <issue>24</issue>
          <fpage>3112</fpage>
          <lpage>3118</lpage>
          <pub-id pub-id-type="doi">10.3748/wjg.v18.i24.3112</pub-id>
          <?supplied-pmid 22791947?>
          <pub-id pub-id-type="pmid">22791947</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ma</surname>
              <given-names>JQ</given-names>
            </name>
            <name>
              <surname>Kurban</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>QZ</given-names>
            </name>
            <name>
              <surname>Hasimu</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Epigenetic regulation of human riboflavin transporter 2(hRFT2) in cervical cancers from Uighur women</article-title>
          <source>Asian Pac J Cancer Prev</source>
          <year>2014</year>
          <volume>15</volume>
          <issue>6</issue>
          <fpage>2485</fpage>
          <lpage>2489</lpage>
          <pub-id pub-id-type="doi">10.7314/APJCP.2014.15.6.2485</pub-id>
          <?supplied-pmid 24761851?>
          <pub-id pub-id-type="pmid">24761851</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jiang</surname>
              <given-names>XR</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>XY</given-names>
            </name>
            <name>
              <surname>Fan</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Guo</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Zhu</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Jiang</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Lu</surname>
              <given-names>SH</given-names>
            </name>
          </person-group>
          <article-title>RFT2 is overexpressed in esophageal squamous cell carcinoma and promotes tumorigenesis by sustaining cell proliferation and protecting against cell death</article-title>
          <source>Cancer Lett</source>
          <year>2014</year>
          <volume>353</volume>
          <issue>1</issue>
          <fpage>78</fpage>
          <lpage>86</lpage>
          <pub-id pub-id-type="doi">10.1016/j.canlet.2014.07.013</pub-id>
          <?supplied-pmid 25045844?>
          <pub-id pub-id-type="pmid">25045844</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fu</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Sun</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Di</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Fan</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Overexpression of riboflavin transporter 2 contributes toward progression and invasion of glioma</article-title>
          <source>NeuroReport</source>
          <year>2016</year>
          <volume>27</volume>
          <issue>15</issue>
          <fpage>1167</fpage>
          <lpage>1173</lpage>
          <pub-id pub-id-type="doi">10.1097/WNR.0000000000000674</pub-id>
          <?supplied-pmid 27584688?>
          <pub-id pub-id-type="pmid">27584688</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lv</surname>
              <given-names>GQ</given-names>
            </name>
            <name>
              <surname>Zou</surname>
              <given-names>HY</given-names>
            </name>
            <name>
              <surname>Liao</surname>
              <given-names>LD</given-names>
            </name>
            <name>
              <surname>Cao</surname>
              <given-names>HH</given-names>
            </name>
            <name>
              <surname>Zeng</surname>
              <given-names>FM</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>BL</given-names>
            </name>
            <name>
              <surname>Xie</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Fang</surname>
              <given-names>WK</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>LY</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>EM</given-names>
            </name>
          </person-group>
          <article-title>Identification of a novel lysyl oxidase-like 2 alternative splicing isoform, LOXL2 Deltae13, in esophageal squamous cell carcinoma</article-title>
          <source>Biochem Cell Biol</source>
          <year>2014</year>
          <volume>92</volume>
          <issue>5</issue>
          <fpage>379</fpage>
          <lpage>389</lpage>
          <pub-id pub-id-type="doi">10.1139/bcb-2014-0046</pub-id>
          <?supplied-pmid 25275797?>
          <pub-id pub-id-type="pmid">25275797</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zeng</surname>
              <given-names>FM</given-names>
            </name>
            <name>
              <surname>Xie</surname>
              <given-names>YM</given-names>
            </name>
            <name>
              <surname>Liao</surname>
              <given-names>LD</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>LY</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Xie</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>LY</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>EM</given-names>
            </name>
          </person-group>
          <article-title>Biological characterization of three immortalized esophageal epithelial cell lines</article-title>
          <source>Mol Med Rep</source>
          <year>2016</year>
          <volume>14</volume>
          <issue>5</issue>
          <fpage>4802</fpage>
          <lpage>4810</lpage>
          <pub-id pub-id-type="doi">10.3892/mmr.2016.5813</pub-id>
          <?supplied-pmid 27748861?>
          <pub-id pub-id-type="pmid">27748861</pub-id>
        </element-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>FR</given-names>
            </name>
            <name>
              <surname>Tao</surname>
              <given-names>LH</given-names>
            </name>
            <name>
              <surname>Shen</surname>
              <given-names>ZY</given-names>
            </name>
            <name>
              <surname>Lv</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>LY</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>EM</given-names>
            </name>
          </person-group>
          <article-title>Fascin expression in human embryonic, fetal, and normal adult tissue</article-title>
          <source>J Histochem Cytochem</source>
          <year>2008</year>
          <volume>56</volume>
          <issue>2</issue>
          <fpage>193</fpage>
          <lpage>199</lpage>
          <pub-id pub-id-type="doi">10.1369/jhc.7A7353.2007</pub-id>
          <?supplied-pmid 17998567?>
          <pub-id pub-id-type="pmid">17998567</pub-id>
        </element-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhao</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Shen</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Shen</surname>
              <given-names>ZY</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>ZY</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>XE</given-names>
            </name>
            <name>
              <surname>Xie</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>JY</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Lu</surname>
              <given-names>XF</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>LY</given-names>
            </name>
          </person-group>
          <article-title>Phosphorylation of fascin decreases the risk of poor survival in patients with esophageal squamous cell carcinoma</article-title>
          <source>J Histochem Cytochem</source>
          <year>2010</year>
          <volume>58</volume>
          <issue>11</issue>
          <fpage>979</fpage>
          <lpage>988</lpage>
          <pub-id pub-id-type="doi">10.1369/jhc.2010.955765</pub-id>
          <?supplied-pmid 20713986?>
          <pub-id pub-id-type="pmid">20713986</pub-id>
        </element-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zeng</surname>
              <given-names>FM</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>XN</given-names>
            </name>
            <name>
              <surname>Shi</surname>
              <given-names>HS</given-names>
            </name>
            <name>
              <surname>Xie</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Du</surname>
              <given-names>ZP</given-names>
            </name>
            <name>
              <surname>Liao</surname>
              <given-names>LD</given-names>
            </name>
            <name>
              <surname>Nie</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>LY</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>EM</given-names>
            </name>
          </person-group>
          <article-title>Fascin phosphorylation sites combine to regulate esophageal squamous cancer cell behavior</article-title>
          <source>Amino Acids</source>
          <year>2017</year>
          <volume>49</volume>
          <issue>5</issue>
          <fpage>943</fpage>
          <lpage>955</lpage>
          <pub-id pub-id-type="doi">10.1007/s00726-017-2398-1</pub-id>
          <?supplied-pmid 28251354?>
          <pub-id pub-id-type="pmid">28251354</pub-id>
        </element-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>HF</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>ZY</given-names>
            </name>
            <name>
              <surname>Tweardy</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Alshareef</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Liao</surname>
              <given-names>LD</given-names>
            </name>
            <name>
              <surname>Xue</surname>
              <given-names>YJ</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>JY</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>XE</given-names>
            </name>
            <name>
              <surname>Gopal</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Gupta</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>LY</given-names>
            </name>
            <name>
              <surname>Lai</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>The opposing function of STAT3 as an oncoprotein and tumor suppressor is dictated by the expression status of STAT3beta in esophageal squamous cell carcinoma</article-title>
          <source>Clin Cancer Res</source>
          <year>2016</year>
          <volume>22</volume>
          <issue>3</issue>
          <fpage>691</fpage>
          <lpage>703</lpage>
          <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-15-1253</pub-id>
          <?supplied-pmid 26405196?>
          <pub-id pub-id-type="pmid">26405196</pub-id>
        </element-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Petteys</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Frank</surname>
              <given-names>EL</given-names>
            </name>
          </person-group>
          <article-title>Rapid determination of vitamin B(2) (riboflavin) in plasma by HPLC</article-title>
          <source>Clin Chim Acta</source>
          <year>2011</year>
          <volume>412</volume>
          <issue>1â2</issue>
          <fpage>38</fpage>
          <lpage>43</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cca.2010.08.037</pub-id>
          <?supplied-pmid 20816949?>
          <pub-id pub-id-type="pmid">20816949</pub-id>
        </element-citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gao</surname>
              <given-names>SY</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Cui</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Lu</surname>
              <given-names>XF</given-names>
            </name>
            <name>
              <surname>Meng</surname>
              <given-names>LY</given-names>
            </name>
            <name>
              <surname>Yuan</surname>
              <given-names>HM</given-names>
            </name>
            <name>
              <surname>Xie</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Du</surname>
              <given-names>ZP</given-names>
            </name>
            <name>
              <surname>Pang</surname>
              <given-names>JX</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>LY</given-names>
            </name>
          </person-group>
          <article-title>Sp1 and AP-1 regulate expression of the human gene VIL2 in esophageal carcinoma cells</article-title>
          <source>J Biol Chem</source>
          <year>2009</year>
          <volume>284</volume>
          <issue>12</issue>
          <fpage>7995</fpage>
          <lpage>8004</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M809734200</pub-id>
          <?supplied-pmid 19164283?>
          <pub-id pub-id-type="pmid">19164283</pub-id>
        </element-citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lu</surname>
              <given-names>XF</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Du</surname>
              <given-names>ZP</given-names>
            </name>
            <name>
              <surname>Xie</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Guo</surname>
              <given-names>ZY</given-names>
            </name>
            <name>
              <surname>Gao</surname>
              <given-names>SY</given-names>
            </name>
            <name>
              <surname>Liao</surname>
              <given-names>LD</given-names>
            </name>
            <name>
              <surname>Shen</surname>
              <given-names>ZY</given-names>
            </name>
            <name>
              <surname>Xie</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>LY</given-names>
            </name>
          </person-group>
          <article-title>Specificity protein 1 regulates fascin expression in esophageal squamous cell carcinoma as the result of the epidermal growth factor/extracellular signal-regulated kinase signaling pathway activation</article-title>
          <source>Cell Mol Life Sci</source>
          <year>2010</year>
          <volume>67</volume>
          <issue>19</issue>
          <fpage>3313</fpage>
          <lpage>3329</lpage>
          <pub-id pub-id-type="doi">10.1007/s00018-010-0382-y</pub-id>
          <?supplied-pmid 20502940?>
          <pub-id pub-id-type="pmid">20502940</pub-id>
        </element-citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>CQ</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>GW</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>ZY</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>YJ</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>XC</given-names>
            </name>
            <name>
              <surname>Xue</surname>
              <given-names>YJ</given-names>
            </name>
            <name>
              <surname>Zhu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>JY</given-names>
            </name>
            <name>
              <surname>Lei</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>QY</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Zheng</surname>
              <given-names>CP</given-names>
            </name>
            <name>
              <surname>Ai</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Tang</surname>
              <given-names>ZD</given-names>
            </name>
            <name>
              <surname>Feng</surname>
              <given-names>CC</given-names>
            </name>
            <name>
              <surname>Liao</surname>
              <given-names>LD</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Shen</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>YJ</given-names>
            </name>
            <name>
              <surname>Bai</surname>
              <given-names>XF</given-names>
            </name>
            <name>
              <surname>He</surname>
              <given-names>JZ</given-names>
            </name>
            <name>
              <surname>Cao</surname>
              <given-names>HH</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>BL</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>Koeffler</surname>
              <given-names>HP</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>LD</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>LY</given-names>
            </name>
          </person-group>
          <article-title>Integrative analyses of transcriptome sequencing identify novel functional lncRNAs in esophageal squamous cell carcinoma</article-title>
          <source>Oncogenesis</source>
          <year>2017</year>
          <volume>6</volume>
          <issue>2</issue>
          <fpage>e297</fpage>
          <pub-id pub-id-type="doi">10.1038/oncsis.2017.1</pub-id>
          <?supplied-pmid 28194033?>
          <pub-id pub-id-type="pmid">28194033</pub-id>
        </element-citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Livak</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>Schmittgen</surname>
              <given-names>TD</given-names>
            </name>
          </person-group>
          <article-title>Analysis of relative gene expression data using real-time quantitative PCR and the 2(âDelta Delta C(T)) Method</article-title>
          <source>Methods</source>
          <year>2001</year>
          <volume>25</volume>
          <issue>4</issue>
          <fpage>402</fpage>
          <lpage>408</lpage>
          <pub-id pub-id-type="doi">10.1006/meth.2001.1262</pub-id>
          <?supplied-pmid 11846609?>
          <pub-id pub-id-type="pmid">11846609</pub-id>
        </element-citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Escarcega</surname>
              <given-names>RO</given-names>
            </name>
            <name>
              <surname>Fuentes-Alexandro</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Garcia-Carrasco</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gatica</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Zamora</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>The transcription factor nuclear factor-kappa B and cancer</article-title>
          <source>Clin Oncol (R Coll Radiol)</source>
          <year>2007</year>
          <volume>19</volume>
          <issue>2</issue>
          <fpage>154</fpage>
          <lpage>161</lpage>
          <pub-id pub-id-type="doi">10.1016/j.clon.2006.11.013</pub-id>
          <pub-id pub-id-type="pmid">17355113</pub-id>
        </element-citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vlahopoulos</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Cen</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Hengen</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Agan</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Moschovi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Critselis</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Adamaki</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bacopoulou</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Copland</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Boldogh</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Karin</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Chrousos</surname>
              <given-names>GP</given-names>
            </name>
          </person-group>
          <article-title>Dynamic aberrant NF-kappaB spurs tumorigenesis: a new model encompassing the microenvironment</article-title>
          <source>Cytokine Growth Factor Rev</source>
          <year>2015</year>
          <volume>26</volume>
          <issue>4</issue>
          <fpage>389</fpage>
          <lpage>403</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cytogfr.2015.06.001</pub-id>
          <?supplied-pmid 26119834?>
          <pub-id pub-id-type="pmid">26119834</pub-id>
        </element-citation>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sheikh</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Death receptor activation complexes: it takes two to activate TNF receptor 1</article-title>
          <source>Cell Cycle</source>
          <year>2003</year>
          <volume>2</volume>
          <issue>6</issue>
          <fpage>550</fpage>
          <lpage>552</lpage>
          <pub-id pub-id-type="doi">10.4161/cc.2.6.566</pub-id>
          <?supplied-pmid 14504472?>
          <pub-id pub-id-type="pmid">14504472</pub-id>
        </element-citation>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Monaco</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Andreakos</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Kiriakidis</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Mauri</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Bicknell</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Foxwell</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Cheshire</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Paleolog</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Feldmann</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Canonical pathway of nuclear factor kappa B activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis</article-title>
          <source>Proc Natl Acad Sci USA</source>
          <year>2004</year>
          <volume>101</volume>
          <issue>15</issue>
          <fpage>5634</fpage>
          <lpage>5639</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.0401060101</pub-id>
          <?supplied-pmid 15064395?>
          <pub-id pub-id-type="pmid">15064395</pub-id>
        </element-citation>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wajant</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Pfizenmaier</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Scheurich</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Tumor necrosis factor signaling</article-title>
          <source>Cell Death Differ</source>
          <year>2003</year>
          <volume>10</volume>
          <issue>1</issue>
          <fpage>45</fpage>
          <lpage>65</lpage>
          <pub-id pub-id-type="doi">10.1038/sj.cdd.4401189</pub-id>
          <?supplied-pmid 12655295?>
          <pub-id pub-id-type="pmid">12655295</pub-id>
        </element-citation>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lin</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>Dinh</surname>
              <given-names>HQ</given-names>
            </name>
            <name>
              <surname>Xie</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Mayakonda</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Silva</surname>
              <given-names>TC</given-names>
            </name>
            <name>
              <surname>Jiang</surname>
              <given-names>YY</given-names>
            </name>
            <name>
              <surname>Ding</surname>
              <given-names>LW</given-names>
            </name>
            <name>
              <surname>He</surname>
              <given-names>JZ</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>XE</given-names>
            </name>
            <name>
              <surname>Hao</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>LY</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Berman</surname>
              <given-names>BP</given-names>
            </name>
            <name>
              <surname>Phillip Koeffler</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Identification of distinct mutational patterns and new driver genes in oesophageal squamous cell carcinomas and adenocarcinomas</article-title>
          <source>Gut</source>
          <year>2017</year>
        </element-citation>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lin</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Koeffler</surname>
              <given-names>HP</given-names>
            </name>
          </person-group>
          <article-title>Genomic and epigenomic aberrations in esophageal squamous cell carcinoma and implications for patients</article-title>
          <source>Gastroenterology</source>
          <year>2017</year>
        </element-citation>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hao</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>Dinh</surname>
              <given-names>HQ</given-names>
            </name>
            <name>
              <surname>Mayakonda</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Jiang</surname>
              <given-names>YY</given-names>
            </name>
            <name>
              <surname>Chang</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Jiang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Lu</surname>
              <given-names>CC</given-names>
            </name>
            <name>
              <surname>Shi</surname>
              <given-names>ZZ</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Cai</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Zhan</surname>
              <given-names>QM</given-names>
            </name>
            <name>
              <surname>Wei</surname>
              <given-names>WQ</given-names>
            </name>
            <name>
              <surname>Berman</surname>
              <given-names>BP</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Koeffler</surname>
              <given-names>HP</given-names>
            </name>
          </person-group>
          <article-title>Spatial intratumoral heterogeneity and temporal clonal evolution in esophageal squamous cell carcinoma</article-title>
          <source>Nat Genet</source>
          <year>2016</year>
          <volume>48</volume>
          <issue>12</issue>
          <fpage>1500</fpage>
          <lpage>1507</lpage>
          <pub-id pub-id-type="doi">10.1038/ng.3683</pub-id>
          <?supplied-pmid 27749841?>
          <pub-id pub-id-type="pmid">27749841</pub-id>
        </element-citation>
      </ref>
      <ref id="CR41">
        <label>41.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jiang</surname>
              <given-names>YY</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>Mayakonda</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hazawa</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ding</surname>
              <given-names>LW</given-names>
            </name>
            <name>
              <surname>Chien</surname>
              <given-names>WW</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Xiao</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Senapedis</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Baloglu</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Kanojia</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Shang</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Tyner</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Koeffler</surname>
              <given-names>HP</given-names>
            </name>
          </person-group>
          <article-title>Targeting super-enhancer-associated oncogenes in oesophageal squamous cell carcinoma</article-title>
          <source>Gut</source>
          <year>2017</year>
          <volume>66</volume>
          <issue>8</issue>
          <fpage>1358</fpage>
          <lpage>1368</lpage>
          <pub-id pub-id-type="doi">10.1136/gutjnl-2016-311818</pub-id>
          <?supplied-pmid 27196599?>
          <pub-id pub-id-type="pmid">27196599</pub-id>
        </element-citation>
      </ref>
      <ref id="CR42">
        <label>42.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sakabe</surname>
              <given-names>NJ</given-names>
            </name>
            <name>
              <surname>de Souza</surname>
              <given-names>SJ</given-names>
            </name>
          </person-group>
          <article-title>Sequence features responsible for intron retention in human</article-title>
          <source>BMC Genom</source>
          <year>2007</year>
          <volume>8</volume>
          <fpage>59</fpage>
          <pub-id pub-id-type="doi">10.1186/1471-2164-8-59</pub-id>
        </element-citation>
      </ref>
      <ref id="CR43">
        <label>43.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Braunschweig</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Barbosa-Morais</surname>
              <given-names>NL</given-names>
            </name>
            <name>
              <surname>Pan</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Nachman</surname>
              <given-names>EN</given-names>
            </name>
            <name>
              <surname>Alipanahi</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Gonatopoulos-Pournatzis</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Frey</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Irimia</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Blencowe</surname>
              <given-names>BJ</given-names>
            </name>
          </person-group>
          <article-title>Widespread intron retention in mammals functionally tunes transcriptomes</article-title>
          <source>Genome Res</source>
          <year>2014</year>
          <volume>24</volume>
          <issue>11</issue>
          <fpage>1774</fpage>
          <lpage>1786</lpage>
          <pub-id pub-id-type="doi">10.1101/gr.177790.114</pub-id>
          <?supplied-pmid 25258385?>
          <pub-id pub-id-type="pmid">25258385</pub-id>
        </element-citation>
      </ref>
      <ref id="CR44">
        <label>44.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ghosal</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sabui</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Said</surname>
              <given-names>HM</given-names>
            </name>
          </person-group>
          <article-title>Identification and characterization of the minimal 5â²-regulatory region of the human riboflavin transporter-3 (SLC52A3) in intestinal epithelial cells</article-title>
          <source>Am J Physiol Cell Physiol</source>
          <year>2015</year>
          <volume>308</volume>
          <issue>2</issue>
          <fpage>C189</fpage>
          <lpage>C196</lpage>
          <pub-id pub-id-type="doi">10.1152/ajpcell.00342.2014</pub-id>
          <?supplied-pmid 25394472?>
          <pub-id pub-id-type="pmid">25394472</pub-id>
        </element-citation>
      </ref>
      <ref id="CR45">
        <label>45.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>LD</given-names>
            </name>
            <name>
              <surname>Zhou</surname>
              <given-names>FY</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>XM</given-names>
            </name>
            <name>
              <surname>Sun</surname>
              <given-names>LD</given-names>
            </name>
            <name>
              <surname>Song</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Jin</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Kong</surname>
              <given-names>GQ</given-names>
            </name>
            <name>
              <surname>Qi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Cui</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>LQ</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>JZ</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>XC</given-names>
            </name>
            <name>
              <surname>Ren</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>ZC</given-names>
            </name>
            <name>
              <surname>Gao</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Yuan</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Wei</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>YR</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>WP</given-names>
            </name>
            <name>
              <surname>Sheyhidin</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>BP</given-names>
            </name>
            <name>
              <surname>Ren</surname>
              <given-names>SW</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Ku</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Fan</surname>
              <given-names>ZM</given-names>
            </name>
            <name>
              <surname>Zhou</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Guo</surname>
              <given-names>ZG</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>XK</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Ai</surname>
              <given-names>YH</given-names>
            </name>
            <name>
              <surname>Shen</surname>
              <given-names>FF</given-names>
            </name>
            <name>
              <surname>Cui</surname>
              <given-names>WY</given-names>
            </name>
            <name>
              <surname>Song</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Guo</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Yuan</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Yue</surname>
              <given-names>WB</given-names>
            </name>
            <name>
              <surname>Feng</surname>
              <given-names>CW</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>HL</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Tian</surname>
              <given-names>JY</given-names>
            </name>
            <name>
              <surname>Lu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Yuan</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Zhu</surname>
              <given-names>WL</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Fu</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Han</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Han</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>HY</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>XM</given-names>
            </name>
            <name>
              <surname>Dong</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Xing</surname>
              <given-names>GL</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Guo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Chang</surname>
              <given-names>ZW</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>HL</given-names>
            </name>
            <name>
              <surname>Guo</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Yuan</surname>
              <given-names>ZQ</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Lu</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>LQ</given-names>
            </name>
            <name>
              <surname>Zhu</surname>
              <given-names>FG</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>XF</given-names>
            </name>
            <name>
              <surname>Feng</surname>
              <given-names>XS</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Gao</surname>
              <given-names>SG</given-names>
            </name>
            <name>
              <surname>Qige</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Bai</surname>
              <given-names>LT</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Lei</surname>
              <given-names>GY</given-names>
            </name>
            <name>
              <surname>Shen</surname>
              <given-names>ZY</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>LQ</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>LY</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>ZY</given-names>
            </name>
            <name>
              <surname>Cao</surname>
              <given-names>WK</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Bao</surname>
              <given-names>ZQ</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Ding</surname>
              <given-names>GC</given-names>
            </name>
            <name>
              <surname>Zhuang</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Zhou</surname>
              <given-names>YF</given-names>
            </name>
            <name>
              <surname>Zheng</surname>
              <given-names>HF</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Zuo</surname>
              <given-names>XB</given-names>
            </name>
            <name>
              <surname>Dong</surname>
              <given-names>ZM</given-names>
            </name>
            <name>
              <surname>Fan</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>He</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Zhou</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>QX</given-names>
            </name>
            <name>
              <surname>Jiao</surname>
              <given-names>XY</given-names>
            </name>
            <name>
              <surname>Lian</surname>
              <given-names>SY</given-names>
            </name>
            <name>
              <surname>Ji</surname>
              <given-names>AF</given-names>
            </name>
            <name>
              <surname>Lu</surname>
              <given-names>XM</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Chang</surname>
              <given-names>FB</given-names>
            </name>
            <name>
              <surname>Lu</surname>
              <given-names>CD</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>ZG</given-names>
            </name>
            <name>
              <surname>Miao</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Fan</surname>
              <given-names>ZL</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>RB</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>Wei</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Kong</surname>
              <given-names>QP</given-names>
            </name>
            <name>
              <surname>Lan</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Fan</surname>
              <given-names>YJ</given-names>
            </name>
            <name>
              <surname>Gao</surname>
              <given-names>FS</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>TY</given-names>
            </name>
            <name>
              <surname>Xie</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>SQ</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>WC</given-names>
            </name>
            <name>
              <surname>Hong</surname>
              <given-names>JY</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Qiu</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Cai</surname>
              <given-names>ZM</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>XJ</given-names>
            </name>
          </person-group>
          <article-title>Genome-wide association study of esophageal squamous cell carcinoma in Chinese subjects identifies susceptibility loci at PLCE1 and C20orf54</article-title>
          <source>Nat Genet</source>
          <year>2010</year>
          <volume>42</volume>
          <issue>9</issue>
          <fpage>759</fpage>
          <lpage>763</lpage>
          <pub-id pub-id-type="doi">10.1038/ng.648</pub-id>
          <?supplied-pmid 20729853?>
          <pub-id pub-id-type="pmid">20729853</pub-id>
        </element-citation>
      </ref>
      <ref id="CR46">
        <label>46.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wu</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>He</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Jia</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Zhou</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Zhan</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Zhai</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Chang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Qiao</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Jin</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Shen</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Guo</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Fu</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Miao</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Tan</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Shen</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Ke</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Zeng</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Genome-wide association study identifies three new susceptibility loci for esophageal squamous-cell carcinoma in Chinese populations</article-title>
          <source>Nat Genet</source>
          <year>2011</year>
          <volume>43</volume>
          <issue>7</issue>
          <fpage>679</fpage>
          <lpage>684</lpage>
          <pub-id pub-id-type="doi">10.1038/ng.849</pub-id>
          <?supplied-pmid 21642993?>
          <pub-id pub-id-type="pmid">21642993</pub-id>
        </element-citation>
      </ref>
      <ref id="CR47">
        <label>47.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tan</surname>
              <given-names>HZ</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>ZY</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>JY</given-names>
            </name>
            <name>
              <surname>Long</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Jiao</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Peng</surname>
              <given-names>YH</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>YW</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>LY</given-names>
            </name>
          </person-group>
          <article-title>Single nucleotide polymorphism rs13042395 in the SLC52A3 gene as a biomarker for regional lymph node metastasis and relapse-free survival of esophageal squamous cell carcinoma patients</article-title>
          <source>BMC Cancer</source>
          <year>2016</year>
          <volume>16</volume>
          <fpage>560</fpage>
          <pub-id pub-id-type="doi">10.1186/s12885-016-2588-3</pub-id>
          <?supplied-pmid 27472962?>
          <pub-id pub-id-type="pmid">27472962</pub-id>
        </element-citation>
      </ref>
      <ref id="CR48">
        <label>48.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mazur-Bialy</surname>
              <given-names>AI</given-names>
            </name>
            <name>
              <surname>Majka</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Wojtas</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Kolaczkowska</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Plytycz</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Strain-specific effects of riboflavin supplementation on zymosan-induced peritonitis in C57BL/6J, BALB/c and CBA mice</article-title>
          <source>Life Sci</source>
          <year>2011</year>
          <volume>88</volume>
          <issue>5â6</issue>
          <fpage>265</fpage>
          <lpage>271</lpage>
          <pub-id pub-id-type="doi">10.1016/j.lfs.2010.11.016</pub-id>
          <?supplied-pmid 21115019?>
          <pub-id pub-id-type="pmid">21115019</pub-id>
        </element-citation>
      </ref>
      <ref id="CR49">
        <label>49.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mazur-Bialy</surname>
              <given-names>AI</given-names>
            </name>
            <name>
              <surname>Pochec</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>HMGB1 inhibition during zymosan-induced inflammation: the potential therapeutic action of riboflavin</article-title>
          <source>Arch Immunol Ther Exp (Warsz)</source>
          <year>2016</year>
          <volume>64</volume>
          <issue>2</issue>
          <fpage>171</fpage>
          <lpage>176</lpage>
          <pub-id pub-id-type="doi">10.1007/s00005-015-0366-6</pub-id>
          <pub-id pub-id-type="pmid">26445809</pub-id>
        </element-citation>
      </ref>
      <ref id="CR50">
        <label>50.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mal</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Dutta</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Bandyopadhyay</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Basu</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Khan</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Bishayi</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Azithromycin in combination with riboflavin decreases the severity of Staphylococcus aureus infection induced septic arthritis by modulating the production of free radicals and endogenous cytokines</article-title>
          <source>Inflamm Res</source>
          <year>2013</year>
          <volume>62</volume>
          <issue>3</issue>
          <fpage>259</fpage>
          <lpage>273</lpage>
          <pub-id pub-id-type="doi">10.1007/s00011-012-0574-z</pub-id>
          <?supplied-pmid 23229721?>
          <pub-id pub-id-type="pmid">23229721</pub-id>
        </element-citation>
      </ref>
      <ref id="CR51">
        <label>51.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ping</surname>
              <given-names>FM</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>ZJ</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>HB</given-names>
            </name>
            <name>
              <surname>Zhai</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>SX</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>YM</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>BW</given-names>
            </name>
            <name>
              <surname>Wei</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Expression of RKIP, E-cadherin and NF-kB p65 in esophageal squamous cell carcinoma and their correlations</article-title>
          <source>Int J Clin Exp Pathol</source>
          <year>2015</year>
          <volume>8</volume>
          <issue>9</issue>
          <fpage>10164</fpage>
          <lpage>10170</lpage>
          <?supplied-pmid 26617724?>
          <pub-id pub-id-type="pmid">26617724</pub-id>
        </element-citation>
      </ref>
      <ref id="CR52">
        <label>52.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nair</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Venkatraman</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Maliekal</surname>
              <given-names>TT</given-names>
            </name>
            <name>
              <surname>Nair</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Karunagaran</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>NF-kappaB is constitutively activated in high-grade squamous intraepithelial lesions and squamous cell carcinomas of the human uterine cervix</article-title>
          <source>Oncogene</source>
          <year>2003</year>
          <volume>22</volume>
          <issue>1</issue>
          <fpage>50</fpage>
          <lpage>58</lpage>
          <pub-id pub-id-type="doi">10.1038/sj.onc.1206043</pub-id>
          <?supplied-pmid 12527907?>
          <pub-id pub-id-type="pmid">12527907</pub-id>
        </element-citation>
      </ref>
      <ref id="CR53">
        <label>53.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tian</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Zang</surname>
              <given-names>WD</given-names>
            </name>
            <name>
              <surname>Hou</surname>
              <given-names>WH</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>HT</given-names>
            </name>
            <name>
              <surname>Xue</surname>
              <given-names>LX</given-names>
            </name>
          </person-group>
          <article-title>Nuclear factor-kB signaling pathway constitutively activated in esophageal squamous cell carcinoma cell lines and inhibition of growth of cells by small interfering RNA</article-title>
          <source>Acta Biochim Biophys Sin (Shanghai)</source>
          <year>2006</year>
          <volume>38</volume>
          <issue>5</issue>
          <fpage>318</fpage>
          <lpage>326</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1745-7270.2006.00166.x</pub-id>
          <pub-id pub-id-type="pmid">16680372</pub-id>
        </element-citation>
      </ref>
      <ref id="CR54">
        <label>54.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mazur-Bialy</surname>
              <given-names>AI</given-names>
            </name>
            <name>
              <surname>Pochec</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Vitamin B2 deficiency enhances the pro-inflammatory activity of adipocyte, consequences for insulin resistance and metabolic syndrome development</article-title>
          <source>Life Sci</source>
          <year>2017</year>
          <volume>178</volume>
          <fpage>9</fpage>
          <lpage>16</lpage>
          <pub-id pub-id-type="doi">10.1016/j.lfs.2017.04.010</pub-id>
          <?supplied-pmid 28414075?>
          <pub-id pub-id-type="pmid">28414075</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record></GetRecord></OAI-PMH>